{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Sinai Health System (Toronto)\nProcedure Date 2024-06-16\nAccession Date 2024-06-17\nReport Date 2024-06-17\nReport Details\nGenome Reference GRCh37 Sequencing Range - Whole genome sequencing (WGS), Repeat expansion anal- ysis\nReferral Reason Clinical\nAnalysis Location Sinai Health System (Toronto) Table of findings: Gene Information Interpretation DPYD 17 c.1658C>G p, Pro553Arg homozy- Tikely pathogenic  gous\nSummary: One likely pathogenic variant detected.. The details regarding the specific mutations are Included below:\nMRN:\nDate: 2024-06-16\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample.\nVariant 1 of 1\nGene DPYD\nVariant c.1658C>6\nAmino\nZygosity homozygous\np.Pro553Arg\nLikely pathogenic\nThe g.97079400C>G variant occurs in chromosome chr] within the DPYD gene , and it causes c.1658C>G change at position 553 in exon 17 causing the mu- tation p.Pro553Arg This mutation has been identified in 48 families, It has a population frequency of 1.59e-03 (696 alleles in 438318 total alleles tested) , indi- cating it is a very rare variant in the general population; It causes an amino acid substitution, which replaces proline with arginine ClinVar and other genomic databases report the DPYD c.1658C>6 variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVOO9943702). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 549064653, 952929095, 430454170\nMRN:\nDate: 2024-06-16\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variantis therefore classified as a likely pathogenic variant; Test Details:\nGenes Analyzed and mRNA sequence (NM_): HISTIHAL and NM_003546.2. TFE3 and NM_006521.6, FOXO3 and NM_001455.4, SMCIA and NM_006306.4, DPYD and NM_000110.4, VTIIA and NM_145206.4, CHNI and NM_001822.7. KDSR and NM_002035.4. RET and NM_020975.6. SEPT9 and NM_OO1113491.1. GNA 13 and NM_006572.6. NTRK3 and NM_001012338.3. CARDI1 and NM_032415.7. MUC17 and NM_001040105.2. 14 total genes tested;\nRecommendations A precision oncology approach is advised: These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment; PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care: Additional testing may be pursued at the physician's discre- tion;\nMethodology Ribo-Zero RNA was sequenced with Whole genome sequencing (WGS) and was analyzed using Repeat expansion analysis covering all coding exons and adjacent intronic regions Target enrichment was performed with hybrid cap- ture (Twist Bioscience), followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK, Annotation was performed in VarSeq using population databases, predictive algorithms, and ClinVar; CNVs were assessed with CNVkit and confirmed by MLPA when applicable; Regions with pseudogene interference, such as PMS2 , were vali- dated using long-range PCR and Sanger sequencing: Mean read depth ex- ceeded 30Ox, with a minimum threshold of 50x. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2), and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes, or Iow-level mosaicism, PMS2 exons 1-15 are not analyzed: In- terpretations reflect current knowledge and may be updated as new evidence\nMRN:\nDate: 2024-06-16\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nemerges:\nMRN:\nDate: 2024-06-16\nPage 4\n1 Mock\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2024-06-16\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2024-06-16\",\n  \"date_received\": \"2024-06-17\",\n  \"date_verified\": \"2024-06-17\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Sinai Health System (Toronto)\",\n  \"testing_laboratory\": \"Sinai Health System (Toronto)\",\n  \"sequencing_scope\": \"Whole genome sequencing (WGS)\",\n  \"tested_genes\": {\n    \"HIST1H4L\": {\n      \"gene_symbol\": \"HIST1H4L\",\n      \"refseq_mrna\": \"NM_003546.2\"\n    },\n    \"TFE3\": {\n      \"gene_symbol\": \"TFE3\",\n      \"refseq_mrna\": \"NM_006521.6\"\n    },\n    \"FOXO3\": {\n      \"gene_symbol\": \"FOXO3\",\n      \"refseq_mrna\": \"NM_001455.4\"\n    },\n    \"SMC1A\": {\n      \"gene_symbol\": \"SMC1A\",\n      \"refseq_mrna\": \"NM_006306.4\"\n    },\n    \"DPYD\": {\n      \"gene_symbol\": \"DPYD\",\n      \"refseq_mrna\": \"NM_000110.4\"\n    },\n    \"VTI1A\": {\n      \"gene_symbol\": \"VTI1A\",\n      \"refseq_mrna\": \"NM_145206.4\"\n    },\n    \"CHN1\": {\n      \"gene_symbol\": \"CHN1\",\n      \"refseq_mrna\": \"NM_001822.7\"\n    },\n    \"KDSR\": {\n      \"gene_symbol\": \"KDSR\",\n      \"refseq_mrna\": \"NM_002035.4\"\n    },\n    \"RET\": {\n      \"gene_symbol\": \"RET\",\n      \"refseq_mrna\": \"NM_020975.6\"\n    },\n    \"SEPT9\": {\n      \"gene_symbol\": \"SEPT9\",\n      \"refseq_mrna\": \"NM_001113491.1\"\n    },\n    \"GNA13\": {\n      \"gene_symbol\": \"GNA13\",\n      \"refseq_mrna\": \"NM_006572.6\"\n    },\n    \"NTRK3\": {\n      \"gene_symbol\": \"NTRK3\",\n      \"refseq_mrna\": \"NM_001012338.3\"\n    },\n    \"CARD11\": {\n      \"gene_symbol\": \"CARD11\",\n      \"refseq_mrna\": \"NM_032415.7\"\n    },\n    \"MUC17\": {\n      \"gene_symbol\": \"MUC17\",\n      \"refseq_mrna\": \"NM_001040105.2\"\n    }\n  },\n  \"num_tested_genes\": \"14\",\n  \"sample_type\": \"Ribo-Zero RNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"DPYD\",\n      \"variant_id\": \"VCV009943702\",\n      \"chromosome\": \"chr1\",\n      \"hgvsg\": \"g.97079400C>G\",\n      \"hgvsc\": \"c.1658C>G\",\n      \"hgvsp\": \"p.Pro553Arg\",\n      \"transcript_id\": \"NM_000110.4\",\n      \"exon\": \"17\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"696\",\n      \"mafan\": \"438318\",\n      \"mafaf\": \"1.59e-03\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"GRCh37\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2024-06-16\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Ribo-Zero RNA Type of analysis: Repeat expansion analysis Referral Reason: Clinical Referring Physician: Dates Collected ~ 2024-06-16 Assessed 5 2024-06-17 Reported ~ 2024-06-17\nResults: One Iikely pathogenic variant detected:\nSummary of Results: Gene Exon Base \" Amino Zygosity Interpretation   Acid DPYD 17 C.1658C>G p Pro553Arg homozygous Likely pathogenic\nGenes Analyzed: 14 total HISTIHAL, TFE3 , FOXO3 , SMCIA, DPYD VTHIA, CHNI , KDSR, RET, SEPT9 , GNA13, NTRK3, CARDII, MUC17,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2024-06-16\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample. Variant 1 of 1 DPYD ( c.1658C>G p.Pro553Arg ) The c.1658C>G variant occurs at position 553 and is located in exon 17 of the DPYD gene , within chromosome chr] It causes an amino acid substitution, which replaces proline with arginine ClinVar and other genomic databases report the DPYD c.1658C>G variant as clinically relevant based on aggregated evidence. This variant is considered Iikely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCV009943702) . Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 168451706, 572489805, 239803304, 412917121, 647510087, 473263077, 374446561, 792122458 In accordance with existing evidence , this variant is therefore classified as a likely pathogenic variant;\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis.  Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context. Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes.  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform. Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2024-06-16\nNote this is @ draft dataset\nland) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox , with a minimum depth threshold of 5Ox. The analytical sensitivity for single nucleotide variants and small indels is >o9%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g.= PMS2 , CHEK2) , and inability to de tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism, PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2024-06-16\",\n  \"date_received\": \"2024-06-17\",\n  \"date_verified\": \"2024-06-17\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"HIST1H4L\": {\n      \"gene_symbol\": \"HIST1H4L\",\n      \"refseq_mrna\": \"\"\n    },\n    \"TFE3\": {\n      \"gene_symbol\": \"TFE3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FOXO3\": {\n      \"gene_symbol\": \"FOXO3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SMC1A\": {\n      \"gene_symbol\": \"SMC1A\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DPYD\": {\n      \"gene_symbol\": \"DPYD\",\n      \"refseq_mrna\": \"\"\n    },\n    \"VTI1A\": {\n      \"gene_symbol\": \"VTI1A\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CHN1\": {\n      \"gene_symbol\": \"CHN1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KDSR\": {\n      \"gene_symbol\": \"KDSR\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RET\": {\n      \"gene_symbol\": \"RET\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SEPT9\": {\n      \"gene_symbol\": \"SEPT9\",\n      \"refseq_mrna\": \"\"\n    },\n    \"GNA13\": {\n      \"gene_symbol\": \"GNA13\",\n      \"refseq_mrna\": \"\"\n    },\n    \"NTRK3\": {\n      \"gene_symbol\": \"NTRK3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CARD11\": {\n      \"gene_symbol\": \"CARD11\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MUC17\": {\n      \"gene_symbol\": \"MUC17\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"14\",\n  \"sample_type\": \"Ribo-Zero RNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"DPYD\",\n      \"variant_id\": \"VCV009943702\",\n      \"chromosome\": \"chr1\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.1658C>G\",\n      \"hgvsp\": \"p.Pro553Arg\",\n      \"transcript_id\": \"NM_000110.4\",\n      \"exon\": \"17\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft MOLECULAR GENETICS LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: North York General Hospi- tal (Toronto)\nProcedure Date 2022-06-25\nAccession Date 2022-06-25\nReport Date 2022-06-26\nReport Details\nGenome Reference GRCh37 Sequencing Range Whole genome sequencing (WGS); Variant analysis\nReferral Reason Clinical\nAnalysis Location London Health Sciences Centre (London) Table of findings: Gene Information Interpretation HNFIA 15 C,89OCZA p.Pro297His  homozy- Variant Of uncertain gous clinical significance\nSummary: One variant of uncertain clinical significance detected . The de- tails regarding the specific mutations are included below:\nMRN:\nDate: 2022-06-25\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One variant of uncertain clinical significance was detected in the sample.\nVariant 1 of 1\nGene HNFIA\nVariant C.89OC>A\nAmino Zygosity p.Pro297His homozygous Variant of uncertain clinical significance 6 The g.120979432C>A variant occurs in chromosome chr12 within the HNFIA gene, and it causes c.890C>A change at position 297 in exon 15 causing the mutation p.Pro297His This mutation has been identified in 42 families. It has a population frequency of 0.00e+00 (0 alleles in 326309 total alleles tested) , indi- cating it is a very rare variant in the general population: It causes an amino acid substitution, which replaces proline with histidine ClinVar and other genomic databases report the HNFIA c.890C>A variant as clinically relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood: At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV007502834). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMedreferences include: 605004076,208424403,294810356,654880479 , 309618777,494294443,757163341\nMRN:\nDate: 2022-06-25\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): GNAQ and NM_002072.5. MLLT3 and NM_004529.4. HNFIA and NM_000545.8. LRRTM4 and NM_001134745.3. HISTZHAB and NM_001034077.4, HISTIHAB and NM_003544.2. 6 total genes tested.\nRecommendations A precision oncology approach is advised: These mutations are known onco- genic drivers, Iinked to constitutive pathway activation: Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre_ tion;\nMethodology Total DNA was sequenced with Whole genome sequencing (WGS) and was an- alyzed using Variant analysis covering all coding exons and adjacent intronic re- gions; Target enrichment was performed with hybrid capture (Twist Bioscience), followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 US - ing BWA-MEM, and variants called with GATK, Annotation waS performed in VarSeq using population databases, predictive algorithms, and ClinVar CNVs were assessed with CNVkit and confirmed by MLPA when applicable. Regions with pseudogene interference, such as PMS2 , were validated using long-range PCR and Sanger sequencing: Mean read depth exceeded 30Ox , with a mini- mum threshold of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs  Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guide- lines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , andinability to detect certain structural variants (e.g., MSHZ inversions) , deepin- tronic changes, or low-level mosaicism. PMS2 exons 11-15 are not analyzed. In- terpretations reflect current knowledge and may be updated as new evidence emerges;\nMRN:\nDate: 2022-06-25\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2022-06-25\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-06-25\",\n  \"date_received\": \"2022-06-25\",\n  \"date_verified\": \"2022-06-26\",\n  \"report_type\": \"Molecular Genetics\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"North York General Hospital (Toronto)\",\n  \"testing_laboratory\": \"London Health Sciences Centre (London)\",\n  \"sequencing_scope\": \"Whole genome sequencing (WGS)\",\n  \"tested_genes\": {\n    \"GNAQ\": {\n      \"gene_symbol\": \"GNAQ\",\n      \"refseq_mrna\": \"NM_002072.5\"\n    },\n    \"MLLT3\": {\n      \"gene_symbol\": \"MLLT3\",\n      \"refseq_mrna\": \"NM_004529.4\"\n    },\n    \"HNF1A\": {\n      \"gene_symbol\": \"HNF1A\",\n      \"refseq_mrna\": \"NM_000545.8\"\n    },\n    \"LRRTM4\": {\n      \"gene_symbol\": \"LRRTM4\",\n      \"refseq_mrna\": \"NM_001134745.3\"\n    },\n    \"HIST2H4B\": {\n      \"gene_symbol\": \"HIST2H4B\",\n      \"refseq_mrna\": \"NM_001034077.4\"\n    },\n    \"HIST1H4B\": {\n      \"gene_symbol\": \"HIST1H4B\",\n      \"refseq_mrna\": \"NM_003544.2\"\n    }\n  },\n  \"num_tested_genes\": \"6\",\n  \"sample_type\": \"Total DNA\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"HNF1A\",\n      \"variant_id\": \"VCV007502834\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"g.120979432C>A\",\n      \"hgvsc\": \"c.890C>A\",\n      \"hgvsp\": \"p.Pro297His\",\n      \"transcript_id\": \"NM_000545.8\",\n      \"exon\": \"15\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"0\",\n      \"mafan\": \"326309\",\n      \"mafaf\": \"0.00e+00\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"GRCh37\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2022-06-25\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Total DNA Type of analysis: Variant analysis Referral Reason: Clinical Referring Physician: Dates Collected ~ 2022-06-25 Assessed 5 2022-06-25 Reported ~ 2022-06-26\nResults: One variant of uncertain clinical significance de- tected;\nSummary of Results: Gene Exon Base Amino zygosity ` Interpretation Acid HNFIA 15 C.8QOC>A p.Pro297Hs homozygous Variant Of uncer- tain clinical signifi- cance\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2022-06-25\nNote this is @ draft dataset\nGenes Analyzed: 6 total GNAQ, MLLT3, HNFIA, LRRTM4, HISTZHAB, HISTIHAB,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2022-06-25\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One variant of uncertain clinical signifi- cance was detected in the sample. Variant 1 of 1 HNFIA c.890C>A p.Pro297His The c.890C>A variant occurs at position 297 and is located in exon 15 of the HNFIA gene , within chromosome chr12 It causes an amino acid substitution, which replaces proline with histidine ClinVar and other genomic databases report the HNFIA c.890C>A variant aS clinically relevant based on aggregated evidence. The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint: This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCVO07502834). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 968101949, 754660852, 479383930 According to ClinVar; the evidence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of un- certain clinical significance\nRecommendations We recommend a precision oncology approach; These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis   Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations. However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context, Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan. Further genetic testing may be required and completed at a physician's discretion. Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes   Target enrichment waS performed using hybrid capture technology (Twist Bioscience), followed by paired-endsequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute). Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix), incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2022-06-25\nNote this is @ draft dataset\ncopy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing  The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 50x. The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g _ PMS2 , CHEK2) , and inability to de- tect certain structural variants (e.g., MSH2 inversion), deep intronic changes, or low-level mosaicism; PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-06-25\",\n  \"date_received\": \"2022-06-25\",\n  \"date_verified\": \"2022-06-26\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"GNAQ\": {\n      \"gene_symbol\": \"GNAQ\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MLLT3\": {\n      \"gene_symbol\": \"MLLT3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"HNF1A\": {\n      \"gene_symbol\": \"HNF1A\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LRRTM4\": {\n      \"gene_symbol\": \"LRRTM4\",\n      \"refseq_mrna\": \"\"\n    },\n    \"HIST2H4B\": {\n      \"gene_symbol\": \"HIST2H4B\",\n      \"refseq_mrna\": \"\"\n    },\n    \"HIST1H4B\": {\n      \"gene_symbol\": \"HIST1H4B\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"6\",\n  \"sample_type\": \"Total DNA\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"HNF1A\",\n      \"variant_id\": \"VCV007502834\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.890C>A\",\n      \"hgvsp\": \"p.Pro297His\",\n      \"transcript_id\": \"NM_000545.8\",\n      \"exon\": \"15\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft MOLECULAR GENETICS LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Hamilton Health Sciences (Hamilton)\nProcedure Date 2025-11-04\nAccession Date 2025-11-04\nReport Date 2025-1 1-05\nReport Details\nGenome Reference NCBI Build 35 Sequencing Range Gene panel, Variant analysis\nReferral Reason Research\nAnalysis Location Kingston Health Sciences Centre (Kingston) Table of findings: Gene Information Interpretation PRDM16 14 C,505C>A p.Leul691le` heterozy- Variant of uncertain goUs clinical significance\nSummary: One variant of uncertain clinical significance detected . The de- tails regarding the specific mutations are included below\nMRN:\nDate: 2025-11-04\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One variant of uncertain clinical significance was detected in the sample.\nVariant 1 of 1\nGene PRDM16\nVariant C.505C>A\nAmino Zygosity pLeul69lle heterozygous Variant of uncertain clinical significance 6 The g.3069672C>A variant occurs in chromosome chr] within the PRDM16 gene, and it causes C.5OSC>A change at position 169 in exon 14 causing the mutation p.Leul69lle This mutation has been identified in 37 families. It has a population frequency of 4,68e-04 (151 alleles in 322990 total alleles tested), indi- cating it is a relatively common variant in the general population: It causes an amino acid substitution, which replaces leucine with isoleucine ClinVar and other genomic databases report the PRDMI6 c.505C>A variant as clinically rel- evant based on aggregated evidence. The clinical implications of this variant are not yet fully understood. At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCVO07265804). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMedreferences include: 154764913,402521025,422302061, 373398385\nMRN:\nDate: 2025-11-04\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): FEV and NM_017521.3. STK19 and NM_032454.1, FANCG and NM_004629.2, CDZO and NM_001252,5, FOXO4 and NM_005938,4, TPM3 and NM 152263,4, LRRK2 and NM_198578,4, PRDMI6andNM_022114.4. EPHA6 and NM_001080448.3. EBF] and NM_024007.5, USP7 and NM_003470.3, DKCI and NM_001363,5, AURKB and NM_004217.4, THBSI and NM_003246.4, TLX3 and NM_021025.4, PRKAG2 and NM_016203.4, CARS and NM_O01194997.1. PHF6 and NM_001015877.2. DCC and NM_005215.4. 19 total genes tested:\nRecommendations A precision oncology approach Is advised. These mutations are known onco- genic drivers, linked to constitutive pathway activation: Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment; PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events. A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre tion;\nMethodology Other RNA fractions was sequenced with Gene panel and was analyzed using Variant analysis covering all coding exons and adjacent intronic regions. Target enrichment was performed with hybrid capture (Twist Bioscience) , followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK. Annotation was performed in VarSeq using pop ulation databases, predictive algorithms, and ClinVar: CNVs were assessed with CNVkit and confirmed by MLPA when applicable. Regions with pseudogene in- terference , such as PMS2 , were validated using long-range PCR and Sanger se- quencing: Mean read depth exceeded 30Ox , with a minimum threshold of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >959 for exon-level CNVs, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain sig- nificance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , and inability to detect certain structuralvariants (e.g.. MSH2 inversions) , deep in-\nMRN:\nDate: 2025-11-04\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Diagnostics phone: 437-416-6470 terpretations reflect current knowledge and may be updated as new evidence tronic changes, or low-level mosaicism; PMSZ exons 1-15 are not analyzed; In- emerges; 1 Mock\nMRN:\nDate: 2025-11-04\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2025-11-04\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2025-11-04\",\n  \"date_received\": \"2025-11-04\",\n  \"date_verified\": \"2025-11-05\",\n  \"report_type\": \"Molecular Genetics\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"Hamilton Health Sciences (Hamilton)\",\n  \"testing_laboratory\": \"Kingston Health Sciences Centre (Kingston)\",\n  \"sequencing_scope\": \"Gene panel\",\n  \"tested_genes\": {\n    \"FEV\": {\n      \"gene_symbol\": \"FEV\",\n      \"refseq_mrna\": \"NM_017521.3\"\n    },\n    \"STK19\": {\n      \"gene_symbol\": \"STK19\",\n      \"refseq_mrna\": \"NM_032454.1\"\n    },\n    \"FANCG\": {\n      \"gene_symbol\": \"FANCG\",\n      \"refseq_mrna\": \"NM_004629.2\"\n    },\n    \"CD70\": {\n      \"gene_symbol\": \"CD70\",\n      \"refseq_mrna\": \"NM_001252.5\"\n    },\n    \"FOXO4\": {\n      \"gene_symbol\": \"FOXO4\",\n      \"refseq_mrna\": \"NM_005938.4\"\n    },\n    \"TPM3\": {\n      \"gene_symbol\": \"TPM3\",\n      \"refseq_mrna\": \"NM_152263.4\"\n    },\n    \"LRRK2\": {\n      \"gene_symbol\": \"LRRK2\",\n      \"refseq_mrna\": \"NM_198578.4\"\n    },\n    \"PRDM16\": {\n      \"gene_symbol\": \"PRDM16\",\n      \"refseq_mrna\": \"NM_022114.4\"\n    },\n    \"EPHA6\": {\n      \"gene_symbol\": \"EPHA6\",\n      \"refseq_mrna\": \"NM_001080448.3\"\n    },\n    \"EBF1\": {\n      \"gene_symbol\": \"EBF1\",\n      \"refseq_mrna\": \"NM_024007.5\"\n    },\n    \"USP7\": {\n      \"gene_symbol\": \"USP7\",\n      \"refseq_mrna\": \"NM_003470.3\"\n    },\n    \"DKC1\": {\n      \"gene_symbol\": \"DKC1\",\n      \"refseq_mrna\": \"NM_001363.5\"\n    },\n    \"AURKB\": {\n      \"gene_symbol\": \"AURKB\",\n      \"refseq_mrna\": \"NM_004217.4\"\n    },\n    \"THBS1\": {\n      \"gene_symbol\": \"THBS1\",\n      \"refseq_mrna\": \"NM_003246.4\"\n    },\n    \"TLX3\": {\n      \"gene_symbol\": \"TLX3\",\n      \"refseq_mrna\": \"NM_021025.4\"\n    },\n    \"PRKAG2\": {\n      \"gene_symbol\": \"PRKAG2\",\n      \"refseq_mrna\": \"NM_016203.4\"\n    },\n    \"CARS\": {\n      \"gene_symbol\": \"CARS\",\n      \"refseq_mrna\": \"NM_001194997.1\"\n    },\n    \"PHF6\": {\n      \"gene_symbol\": \"PHF6\",\n      \"refseq_mrna\": \"NM_001015877.2\"\n    },\n    \"DCC\": {\n      \"gene_symbol\": \"DCC\",\n      \"refseq_mrna\": \"NM_005215.4\"\n    }\n  },\n  \"num_tested_genes\": \"19\",\n  \"sample_type\": \"Other RNA fractions\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"PRDM16\",\n      \"variant_id\": \"VCV007265804\",\n      \"chromosome\": \"chr1\",\n      \"hgvsg\": \"g.3069672C>A\",\n      \"hgvsc\": \"c.505C>A\",\n      \"hgvsp\": \"p.Leu169Ile\",\n      \"transcript_id\": \"NM_022114.4\",\n      \"exon\": \"14\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"151\",\n      \"mafan\": \"322990\",\n      \"mafaf\": \"4.68e-04\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"NCBI Build 35\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2025-11-04\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Other RNA fractions Type of analysis: Variant analysis Referral Reason: Research Referring Physician: Dates Collected ~ 2025-11-04 Assessed 5 2025-11-04 Reported ~ 2025-11-05\nResults: One variant of uncertain clinical significance de- tected;\nSummary of Results: Gene Exon Base Amino Acid PRDMT6 14 C,505C>A p.Leu191le \nzygosity `\nInterpretation\nheterozygous Variant Of uncer- tain clinical signifi- cance\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2025-11-04\nNote this is @ draft dataset\nGenes Analyzed: 19 total FEV, STKI9, FANCG, CD7O, FOXO4, TPM3 , LRRK2 , PRDM16, EPHA6 , EBFI, USP7, DKCI, AURKB, THBSI , TLX3 , PRKAG2, CARS, PHF6, DCC ,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2025-11-04\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One variant of uncertain clinical signifi- cance was detected in the sample. Variant 1 of 1 PRDM16 c.505C>A p.Leul69lle ) The c.505C>A variant occurs at position 169 and is located in exon 14 of the PRDMI6 gene , within chromosome chr] It causes an amino acid substitution, which replaces leucine with isoleucine ClinVar and other genomic databases report the PRDM16 C.505C>A variant aS clinically relevant based on aggregated evidence. The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease_ The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint: This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV007265804). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 779199999,411471776, 984123282, 600236788 According to ClinVar; the evidence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance\nRecommendations We recommend a precision oncology approach; These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis   Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations. However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context, Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan. Further genetic testing may be required and completed at a physician's discretion. Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes   Target enrichment waS performed using hybrid capture technology (Twist Bioscience), followed by paired-endsequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute). Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix), incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2025-11-04\nNote this is @ draft dataset\ncopy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing  The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 50x. The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g _ PMS2 , CHEK2) , and inability to de- tect certain structural variants (e.g., MSH2 inversion), deep intronic changes, or low-level mosaicism; PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2025-11-04\",\n  \"date_received\": \"2025-11-04\",\n  \"date_verified\": \"2025-11-05\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"FEV\": {\n      \"gene_symbol\": \"FEV\",\n      \"refseq_mrna\": \"\"\n    },\n    \"STK19\": {\n      \"gene_symbol\": \"STK19\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FANCG\": {\n      \"gene_symbol\": \"FANCG\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CD70\": {\n      \"gene_symbol\": \"CD70\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FOXO4\": {\n      \"gene_symbol\": \"FOXO4\",\n      \"refseq_mrna\": \"\"\n    },\n    \"TPM3\": {\n      \"gene_symbol\": \"TPM3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LRRK2\": {\n      \"gene_symbol\": \"LRRK2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PRDM16\": {\n      \"gene_symbol\": \"PRDM16\",\n      \"refseq_mrna\": \"\"\n    },\n    \"EPHA6\": {\n      \"gene_symbol\": \"EPHA6\",\n      \"refseq_mrna\": \"\"\n    },\n    \"EBF1\": {\n      \"gene_symbol\": \"EBF1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"USP7\": {\n      \"gene_symbol\": \"USP7\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DKC1\": {\n      \"gene_symbol\": \"DKC1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"AURKB\": {\n      \"gene_symbol\": \"AURKB\",\n      \"refseq_mrna\": \"\"\n    },\n    \"THBS1\": {\n      \"gene_symbol\": \"THBS1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"TLX3\": {\n      \"gene_symbol\": \"TLX3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PRKAG2\": {\n      \"gene_symbol\": \"PRKAG2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CARS\": {\n      \"gene_symbol\": \"CARS\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PHF6\": {\n      \"gene_symbol\": \"PHF6\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DCC\": {\n      \"gene_symbol\": \"DCC\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"19\",\n  \"sample_type\": \"Other RNA fractions\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"PRDM16\",\n      \"variant_id\": \"VCV007265804\",\n      \"chromosome\": \"chr1\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.505C>A\",\n      \"hgvsp\": \"p.Leu169Ile\",\n      \"transcript_id\": \"NM_022114.4\",\n      \"exon\": \"14\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2020-05-02\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Total DNA Type of analysis: Fusion analysis Referral Reason: Research Referring Physician: Dates Collected ~ 2020-05-02 Assessed ~ 2020-05-02 Reported ~ 2020-05-03\nResults: One Iikely pathogenic variant detected:\nSummary of Results: Gene Exon Base Amino Acid CZorf44 16 C.5166>A p.Val172=\nZygosity\nInterpretation  \nheterozygous_ Likely pathogenic\nGenes Analyzed: 15 total PRDMI, DNM2, CDX2, SMARCBI, RSPO2, CTNNA2, COLIIAI, ELF4, MBDI, LPP, AKTI, LYN, PAK3, FANCF, C2orf44,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2020-05-02\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One likely pathogenic variant was de tected in the sample. Variant 1 of 1 C2orf44 c.516G>A p.Vall72= ) The c.516G>A variant occurs at position 172 and is located in exon 16 of the C2orf44 gene, within chromosome chr2 It causes no amino acid change. ClinVar and other genomic databases report the C2orf44 c.516G>A variant as clinically relevant based on aggregated evidence. This variant is considered likely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVOO1037284). Supporting studies and case reports can be found in the scientific literature, Relevant PubMed references include: 735412060,784926767, 762931569 In accordance with existing evidence , this variant is therefore classified as & likely pathogenic variant;\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis.  Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context. Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes.  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform. Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2020-05-02\nNote this is @ draft dataset\nland) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox , with a minimum depth threshold of 5Ox. The analytical sensitivity for single nucleotide variants and small indels is >o9%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g.= PMS2 , CHEK2) , and inability to de tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism, PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2020-05-02\",\n  \"date_received\": \"2020-05-02\",\n  \"date_verified\": \"2020-05-03\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"PRDM1\": {\n      \"gene_symbol\": \"PRDM1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DNM2\": {\n      \"gene_symbol\": \"DNM2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CDX2\": {\n      \"gene_symbol\": \"CDX2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SMARCB1\": {\n      \"gene_symbol\": \"SMARCB1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RSPO2\": {\n      \"gene_symbol\": \"RSPO2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CTNNA2\": {\n      \"gene_symbol\": \"CTNNA2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"COL11A1\": {\n      \"gene_symbol\": \"COL11A1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ELF4\": {\n      \"gene_symbol\": \"ELF4\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MBD1\": {\n      \"gene_symbol\": \"MBD1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LPP\": {\n      \"gene_symbol\": \"LPP\",\n      \"refseq_mrna\": \"\"\n    },\n    \"AKT1\": {\n      \"gene_symbol\": \"AKT1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LYN\": {\n      \"gene_symbol\": \"LYN\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PAK3\": {\n      \"gene_symbol\": \"PAK3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FANCF\": {\n      \"gene_symbol\": \"FANCF\",\n      \"refseq_mrna\": \"\"\n    },\n    \"C2orf44\": {\n      \"gene_symbol\": \"C2orf44\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"15\",\n  \"sample_type\": \"Total DNA\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"C2orf44\",\n      \"variant_id\": \"VCV001037284\",\n      \"chromosome\": \"chr2\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.516G>A\",\n      \"hgvsp\": \"p.Val172=\",\n      \"transcript_id\": \"NM_025203.2\",\n      \"exon\": \"16\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft MOLECULAR GENETICS LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Lakeridge Health (Os- hawa)\nProcedure Date 2020-05-02\nAccession Date 2020-05-02\nReport Date 2020-05-03\nReport Details\nGenome Reference GRCh38 Sequencing Range Gene panel, Fusion analysis\nReferral Reason Research\nAnalysis Location Children's Hospital of Eastern Ontario (Ottawa) Table of findings: Gene Information Interpretation CZorf44 T6 C,S16GXAp,ValT72=heterozygous Zikely pathogenic \nSummary: One likely pathogenic variant detected:_ The details regarding the specific mutations are included below:\nMRN:\nDate: 2020-05-02\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample.\nVariant 1 of 1\nGene CZorf44\nVariant c,5166>A\nAmino Zygosity pVal172= heterozygous Likely pathogenic 3 The g.242527256>A variant occurs in chromosome chr2 within the C2orf44 gene, and it causes c.516G>A change at position 172 in exon 16 causing the mutation p.Val172= This mutation has been identified in 45 families; It has a population frequency of 5.43e-04 (227 alleles in 418208 total alleles tested), indi- cating it is a relatively common variant in the general population; It causes no amino acid change. ClinVar and other genomic databases report the C2orf44 c.516G>A variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVO01037284). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 448026965,649335732, 550927079\nMRN:\nDate: 2020-05-02\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variantis therefore classified as a likely pathogenic variant; Test Details:\nGenes Analyzed and mRNA sequence (NM_): PRDMI and NM_001198,4, DNM2 and NM_O01005361.3. CDX2 and NM_001265.6. SMARCBI and NM_001317946.2. RSPO2 and NM_178565.5, CTNNA? and NM_001282597.3, COLIIAI andNM_001854,4, ELFA and NM_001421.4, MBDI and NM_015846.4., LPP and NM_001387670.1, AKTI and NM_001382433.1 , LYN and NM_002350.4, PAK3 and NM_002578,5, FANCF and NM_022725.4. C2orf44 and NM_025203.2. 15 total genes tested.\nRecommendations A precision oncology approach is advised: These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment; PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care: Additional testing may be pursued at the physician's discre- tion;\nMethodology Total DNA was sequenced with Gene panel and waS analyzed using Fusion analysis covering all coding exons and adjacent intronic regions Target en- richment was performed with hybrid capture (Twist Bioscience) , followed by I1- lumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK. Annotation was performed in VarSeq using pop ulation databases, predictive algorithms, and ClinVar CNVs were assessed with CNVkit and confirmed by MLPA when applicable; Regions with pseudogene in- terference , such as PMS2 , were validated using long-range PCR and Sanger se- quencing: Mean read depth exceeded 30Ox, with a minimum threshold of 5Ox. Analytical sensitivity is >99% for SNVs /indels and >95% for exon-level CNVs, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain sig- nificance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMSZ , CHEK2) - and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes , or low-level mosaicism; PMS2 exons 11-15 are not analyzed, In- terpretations reflect current knowledge and may be updated as new evidence emerges:\nMRN:\nDate: 2020-05-02\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2020-05-02\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2020-05-02\",\n  \"date_received\": \"2020-05-02\",\n  \"date_verified\": \"2020-05-03\",\n  \"report_type\": \"Molecular Genetics\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"Lakeridge Health (Oshawa)\",\n  \"testing_laboratory\": \"Children's Hospital of Eastern Ontario (Ottawa)\",\n  \"sequencing_scope\": \"Gene panel\",\n  \"tested_genes\": {\n    \"PRDM1\": {\n      \"gene_symbol\": \"PRDM1\",\n      \"refseq_mrna\": \"NM_001198.4\"\n    },\n    \"DNM2\": {\n      \"gene_symbol\": \"DNM2\",\n      \"refseq_mrna\": \"NM_001005361.3\"\n    },\n    \"CDX2\": {\n      \"gene_symbol\": \"CDX2\",\n      \"refseq_mrna\": \"NM_001265.6\"\n    },\n    \"SMARCB1\": {\n      \"gene_symbol\": \"SMARCB1\",\n      \"refseq_mrna\": \"NM_001317946.2\"\n    },\n    \"RSPO2\": {\n      \"gene_symbol\": \"RSPO2\",\n      \"refseq_mrna\": \"NM_178565.5\"\n    },\n    \"CTNNA2\": {\n      \"gene_symbol\": \"CTNNA2\",\n      \"refseq_mrna\": \"NM_001282597.3\"\n    },\n    \"COL11A1\": {\n      \"gene_symbol\": \"COL11A1\",\n      \"refseq_mrna\": \"NM_001854.4\"\n    },\n    \"ELF4\": {\n      \"gene_symbol\": \"ELF4\",\n      \"refseq_mrna\": \"NM_001421.4\"\n    },\n    \"MBD1\": {\n      \"gene_symbol\": \"MBD1\",\n      \"refseq_mrna\": \"NM_015846.4\"\n    },\n    \"LPP\": {\n      \"gene_symbol\": \"LPP\",\n      \"refseq_mrna\": \"NM_001387670.1\"\n    },\n    \"AKT1\": {\n      \"gene_symbol\": \"AKT1\",\n      \"refseq_mrna\": \"NM_001382433.1\"\n    },\n    \"LYN\": {\n      \"gene_symbol\": \"LYN\",\n      \"refseq_mrna\": \"NM_002350.4\"\n    },\n    \"PAK3\": {\n      \"gene_symbol\": \"PAK3\",\n      \"refseq_mrna\": \"NM_002578.5\"\n    },\n    \"FANCF\": {\n      \"gene_symbol\": \"FANCF\",\n      \"refseq_mrna\": \"NM_022725.4\"\n    },\n    \"C2orf44\": {\n      \"gene_symbol\": \"C2orf44\",\n      \"refseq_mrna\": \"NM_025203.2\"\n    }\n  },\n  \"num_tested_genes\": \"15\",\n  \"sample_type\": \"Total DNA\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"C2orf44\",\n      \"variant_id\": \"VCV001037284\",\n      \"chromosome\": \"chr2\",\n      \"hgvsg\": \"g.24252725G>A\",\n      \"hgvsc\": \"c.516G>A\",\n      \"hgvsp\": \"p.Val172=\",\n      \"transcript_id\": \"NM_025203.2\",\n      \"exon\": \"16\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"227\",\n      \"mafan\": \"418208\",\n      \"mafaf\": \"5.43e-04\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"GRCh38\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2022-11-13\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Other DNA enrichments Type of analysis: Variant analysis Referral Reason: Clinical Referring Physician: Dates Collected ~ 2022-11-13 Assessed 5 2022-11-14 Reported ~ 2022-11-15\nResults: one likely pathogenic variant and one variant of uncertain clinical signifi- cance detected:\nSummary of Results: Gene Exon Base Amino zygosity Tnterpretation Acid ERCCS C,I9A>G p.Lys6AGlu homozygous_ @ikely pathogenic KMT2D C,160266> p,G1u5342Asp1 heterozygous Variant Of uncer- tain clinical signifi- cance\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2022-11-13\nNote this is @ draft dataset\nGenes Analyzed: 6 total RHOH, ERCC5, ERCC3 , KMTZD, MSH2 , RNF217,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2022-11-13\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample. Variant 1 of 2 ERCC5 c.I9OA>G p.LysbAGlu ) The c.]QA>G variant occurs at position 64 and is located in exon 1 of the ERCC5 gene, within chromosome chr]3 It causes an amino acid substitution, which replaces lysine with glutamate ClinVar and other genomic databases report the ERCC5 c.] 90A>G variant as clinically relevant based on aggregated evidence. This variant is considered Iikely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCV008239518). Supporting studies and case reports can be found in the scientific literature, Relevant PubMed references include: 801403876,877018440 , 787415724,659665532 In accordance with existing evidence , this variant is therefore clas- sified as a likely pathogenic variant; Variant 2 of 2 KMT2D ( c.16026G>C p.Glu5342Asp ) The c.160266>C variant occurs at position 5342 and is locatedin exon 5 of the KMTZD gene , within chromosome chr12 It causes an amino acid substitution, which replaces glutamate with aspartate ClinVar and other genomic databases report the KMTZD c.160266>C vari- ant as clinically relevant based on aggregated evidence. The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV004453704). Supporting studies and case reports can be found in the scientific literature. Relevant PubMedreferences include: 684828718, 525297906, 382435336 According to ClinVar, the evidence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of un- certain clinical significance\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis; Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2022-11-13\nNote this is @ draft dataset\ntionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context, Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events; Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute). Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogeneinterference, such as PMS2 ,_ were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 5Ox, The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMG/AMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory. Limitations include reduced sensitivity in regions with pseudogenes (e.g., PMSZ , CHEK2) , and inability to de- tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism; PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-11-13\",\n  \"date_received\": \"2022-11-14\",\n  \"date_verified\": \"2022-11-15\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"RHOH\": {\n      \"gene_symbol\": \"RHOH\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ERCC5\": {\n      \"gene_symbol\": \"ERCC5\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ERCC3\": {\n      \"gene_symbol\": \"ERCC3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KMT2D\": {\n      \"gene_symbol\": \"KMT2D\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MSH2\": {\n      \"gene_symbol\": \"MSH2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RNF217\": {\n      \"gene_symbol\": \"RNF217\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"6\",\n  \"sample_type\": \"Other DNA enrichments\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"ERCC5\",\n      \"variant_id\": \"VCV008239518\",\n      \"chromosome\": \"chr13\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.190A>G\",\n      \"hgvsp\": \"p.Lys64Glu\",\n      \"transcript_id\": \"NM_000123.4\",\n      \"exon\": \"1\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    },\n    {\n      \"gene_symbol\": \"KMT2D\",\n      \"variant_id\": \"VCV004453704\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.16026G>C\",\n      \"hgvsp\": \"p.Glu5342Asp\",\n      \"transcript_id\": \"NM_003482.4\",\n      \"exon\": \"5\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Sinai Health System (Toronto)\nProcedure Date 2022-11-13\nAccession Date 2022-11-14\nReport Date 2022-11-15\nReport Details\nGenome Reference NCBI Build 36.1 Sequencing Range Whole transcriptome sequencing (WTS) , Variant analysis\nReferral Reason Clinical\nAnalysis Location Children's Hospital of Eastern Ontario (Ottawa) Table of findings: Gene Information Interpretation ERCC5 C,TOOA>G p.Lys6AClu homozygous Zikely pathogenic  KMTZD 5 C.160266>C p.Glu5342Asp het- Variant of uncertain erozygous clinical significance\nSummary: one likely pathogenic variant and one variant of uncertain clin- ical significance detected. The details regarding the specific mutations are included below.\nMRN:\nDate: 2022-11-13\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample \nVariant 1 of 2\nGene ERCC5\nVariant c.IQOA>G\nAmino Zygosity p.Lys6AGlu homozygous Likely pathogenic 6 The 9.102846020A>G variant occurs in chromosome chr13 within the ERCC5 gene, and it causes c.]QOA>G change at position 64 in exon 1 causing the mutation pLys6AGlu This mutation has been identified in 38 families, It has a population frequency of 0.00e+00 (0 alleles in 445181 total alleles tested) , indi- cating it is a very rare variant in the general population; It causes an amino acid substitution, which replaces lysine with glutamate ClinVar and other genomic databases report the ERCCS c.19OA>G variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCV008239518). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMedreferences include: 641830270,858155673, 597315409, 823201565\nMRN:\nDate: 2022-11-13\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variant is therefore classified as a likely pathogenic variant;\nVariant 2 of 2\nGene KMTZD\nVariant\nAmino\nZygosity heterozygous\nC.160266>C\np.Glu5342Asp\nVariant of uncertain clinical significance\nThe g.49035000G>C variant occurs in chromosome chr12 within the KMTZD gene, and it causes c.160266>C change at position 5342 in exon 5 causing the mutation p.Glu5342Asp This mutation has been identified in 33 families; It has a population frequency of 3.28e-04 (188 alleles in 573309 total alleles tested), indicating it is a relatively common variant in the general population: It causes an amino acid substitution, which replaces glutamate with aspartate ClinVar and other genomic databases report the KMTZD c.160266>C variant as clini- cally relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood, At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV004453704). Supporting studies and case reports can be found in the scientific literature: Rel- evant PubMedreferences include: 650821679,887029833, 352490932, 793722424\nMRN:\nDate: 2022-11-13\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): RHOHand NM_004310.5. ERCC5 and NM_000123,4, ERCC3 and NM_001303418.2, KMTZD and NM_003482.4, MSHZ and NM_000251,3. RNF2I7 and NM_001286398.3, 6 total genes tested,\nRecommendations A precision oncology approach is advised: These mutations are known onco- genic drivers, Iinked to constitutive pathway activation: Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre_ tion;\nMethodology Other DNA enrichments was sequenced with Whole transcriptome sequencing (WTS) and was analyzed using Variant analysis covering all coding exons and adjacent intronic regions; Target enrichment was performed with hybrid cap ture (Twist Bioscience) , followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK, Annotation waS performed in VarSeq using population databases, predictive algorithms , and ClinVar; CNVs were assessed with CNVkit and confirmed by MLPA when applicable. Regions with pseudogene interference, such as PMS2 , were vali- dated using long-range PCR and Sanger sequencing: Mean read depth ex- ceeded 30Ox, with a minimum threshold of 5Ox, Analytical sensitivity is >o9% for SNVs/indels and >95% for exon-level CNVs, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , andinability to detect certain structural variants (e.g., MSHZ inversions) , deepin- tronic changes, or low-level mosaicism. PMS2 exons 11-15 are not analyzed. In- terpretations reflect current knowledge and may be updated as new evidence emerges;\nMRN:\nDate: 2022-11-13\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2022-11-13\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-11-13\",\n  \"date_received\": \"2022-11-14\",\n  \"date_verified\": \"2022-11-15\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Sinai Health System (Toronto)\",\n  \"testing_laboratory\": \"Children's Hospital of Eastern Ontario (Ottawa)\",\n  \"sequencing_scope\": \"Whole transcriptome sequencing (WTS)\",\n  \"tested_genes\": {\n    \"RHOH\": {\n      \"gene_symbol\": \"RHOH\",\n      \"refseq_mrna\": \"NM_004310.5\"\n    },\n    \"ERCC5\": {\n      \"gene_symbol\": \"ERCC5\",\n      \"refseq_mrna\": \"NM_000123.4\"\n    },\n    \"ERCC3\": {\n      \"gene_symbol\": \"ERCC3\",\n      \"refseq_mrna\": \"NM_001303418.2\"\n    },\n    \"KMT2D\": {\n      \"gene_symbol\": \"KMT2D\",\n      \"refseq_mrna\": \"NM_003482.4\"\n    },\n    \"MSH2\": {\n      \"gene_symbol\": \"MSH2\",\n      \"refseq_mrna\": \"NM_000251.3\"\n    },\n    \"RNF217\": {\n      \"gene_symbol\": \"RNF217\",\n      \"refseq_mrna\": \"NM_001286398.3\"\n    }\n  },\n  \"num_tested_genes\": \"6\",\n  \"sample_type\": \"Other DNA enrichments\",\n  \"analysis_type\": \"Variant analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"ERCC5\",\n      \"variant_id\": \"VCV008239518\",\n      \"chromosome\": \"chr13\",\n      \"hgvsg\": \"g.102846020A>G\",\n      \"hgvsc\": \"c.190A>G\",\n      \"hgvsp\": \"p.Lys64Glu\",\n      \"transcript_id\": \"NM_000123.4\",\n      \"exon\": \"1\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"0\",\n      \"mafan\": \"445181\",\n      \"mafaf\": \"0.00e+00\"\n    },\n    {\n      \"gene_symbol\": \"KMT2D\",\n      \"variant_id\": \"VCV004453704\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"g.49035000G>C\",\n      \"hgvsc\": \"c.16026G>C\",\n      \"hgvsp\": \"p.Glu5342Asp\",\n      \"transcript_id\": \"NM_003482.4\",\n      \"exon\": \"5\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"188\",\n      \"mafan\": \"573309\",\n      \"mafaf\": \"3.28e-04\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"NCBI Build 36.1\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Sinai Health System (Toronto)\nProcedure Date 2022-02-14\nAccession Date 2022-02-16\nReport Date 2022-02-18\nReport Details\nGenome Reference GRCh37 Sequencing Range Whole transcriptome sequencing (WTS) , Repeat expan- sion analysis\nReferral Reason Clinical\nAnalysis Location London Health Sciences Centre (London) Table of findings: Gene Information Interpretation RPST5 1 C.3766>C p,Val 126Leu heterozy- @ikely pathogenic gous RPS15 1 c.756>T p.Leu2s= heterozygous Variant of uncertain clinical significance\nSummary: one likely pathogenic variant and one variant of uncertain clin- ical significance detected, The details regarding the specific mutations are included below.\nMRN:\nDate: 2022-02-14\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample \nVariant 1 of 2\nGene RPS15\nVariant c.3766>C\nAmino\nZygosity heterozygous\np.Val126Leu\nLikely pathogenic\nThe g.14387336>C variant occurs in chromosome chr1 9 within the RPSI 5 gene , andit causes ,3766>C change at position 126in exon causing the mutation p.Val126Leu This mutation has been identified in 40 families, It has a popula- tion frequency of 0.OOe+OO (0 alleles in 411154 total alleles tested), indicating it is a very rare variant in the general population. It causes an amino acid substitu- tion, which replaces valine with leucine ClinVar and other genomic databases report the RPSI5 c,3766>C variant as clinically relevant based on aggregated evidence, This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVO01282991). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMedreferences include: 590188745, 103495133,696175833,234804937, 209643931, 820165027,937760923,617733054\nMRN:\nDate: 2022-02-14\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variant is therefore classified as a likely pathogenic variant;\nVariant 2 of 2\nGene RPS15\nVariant c.756>T\nAmino pLeu2s=\nZygosity heterozygous\nVariant of uncertain clinical significance\nThe g.1438432G>Tvariant occurs in chromosome chr1 9 within the RPS15 gene , and it causes c.75G>T change at position 25 in exon causing the mutation p.Leu25= This mutation has been identified in 39 families, It has a population frequency of 0.0Oe+00 (0 alleles in 641275 total alleles tested) , indicating it is a very rare variant in the general population. It causes no amino acid change. ClinVar and other genomic databases report the RPSI5 c.75G>Tvariant as clin- ically relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood: At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV000646780). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMed references include: 499711459,828083862,249108188,785749409_ 820316936, 921612426,371512347\nMRN:\nDate: 2022-02-14\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): PREX2 and NM_024870.4. FANCE and NM_021922.3, RPS15 and NM_OO1018,5, RADSO and NM_005732.4, NUPO8 and NM_016320.5. CHDA and NM_O01273.5. KDM3B and NM_016604,4, LPP and NM_001387670.1, 8 total genes tested;\nRecommendations A precision oncology approach Is advised. These mutations are known onco- genic drivers, Iinked to constitutive pathway activation: Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre- tion:\nMethodology CtDNA waS sequenced with Whole transcriptome sequencing (WTS) and was analyzed using Repeat expansion analysis covering all coding exons and ad- jacent intronic regions  Target enrichment was performed with hybrid capture (Twist Bioscience), followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, andvariants called with GATK. Annotation was per- formed in VarSeq using population databases, predictive algorithms , and Clin- Var: CNVs were assessed with CNVkit and confirmed by MLPA when applica- ble. Regions with pseudogene interference, such as PMS2 , were validated using long-range PCR and Sanger sequencing: Mean read depth exceeded 30Ox , with a minimum threshold of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMG/AMP guidelines (PMID: 25741868). Limitations This test waS developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes , or low-level mosaicism; PMS2 exons 11-15 are not analyzed, In- terpretations reflect current knowledge and may be updated as new evidence emerges:\nMRN:\nDate: 2022-02-14\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2022-02-14\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-02-14\",\n  \"date_received\": \"2022-02-16\",\n  \"date_verified\": \"2022-02-18\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Sinai Health System (Toronto)\",\n  \"testing_laboratory\": \"London Health Sciences Centre (London)\",\n  \"sequencing_scope\": \"Whole transcriptome sequencing (WTS)\",\n  \"tested_genes\": {\n    \"PREX2\": {\n      \"gene_symbol\": \"PREX2\",\n      \"refseq_mrna\": \"NM_024870.4\"\n    },\n    \"FANCE\": {\n      \"gene_symbol\": \"FANCE\",\n      \"refseq_mrna\": \"NM_021922.3\"\n    },\n    \"RPS15\": {\n      \"gene_symbol\": \"RPS15\",\n      \"refseq_mrna\": \"NM_001018.5\"\n    },\n    \"RAD50\": {\n      \"gene_symbol\": \"RAD50\",\n      \"refseq_mrna\": \"NM_005732.4\"\n    },\n    \"NUP98\": {\n      \"gene_symbol\": \"NUP98\",\n      \"refseq_mrna\": \"NM_016320.5\"\n    },\n    \"CHD4\": {\n      \"gene_symbol\": \"CHD4\",\n      \"refseq_mrna\": \"NM_001273.5\"\n    },\n    \"KDM3B\": {\n      \"gene_symbol\": \"KDM3B\",\n      \"refseq_mrna\": \"NM_016604.4\"\n    },\n    \"LPP\": {\n      \"gene_symbol\": \"LPP\",\n      \"refseq_mrna\": \"NM_001387670.1\"\n    }\n  },\n  \"num_tested_genes\": \"8\",\n  \"sample_type\": \"ctDNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"RPS15\",\n      \"variant_id\": \"VCV001282991\",\n      \"chromosome\": \"chr19\",\n      \"hgvsg\": \"g.1438733G>C\",\n      \"hgvsc\": \"c.376G>C\",\n      \"hgvsp\": \"p.Val126Leu\",\n      \"transcript_id\": \"NM_001018.5\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"0\",\n      \"mafan\": \"411154\",\n      \"mafaf\": \"0.00e+00\"\n    },\n    {\n      \"gene_symbol\": \"RPS15\",\n      \"variant_id\": \"VCV000646780\",\n      \"chromosome\": \"chr19\",\n      \"hgvsg\": \"g.1438432G>T\",\n      \"hgvsc\": \"c.75G>T\",\n      \"hgvsp\": \"p.Leu25=\",\n      \"transcript_id\": \"NM_001018.5\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"0\",\n      \"mafan\": \"641275\",\n      \"mafaf\": \"0.00e+00\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"GRCh37\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2022-02-14\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: ctDNA Type of analysis: Repeat expansion analysis Referral Reason: Clinical Referring Physician: Dates Collected ~ 2022-02-14 Assessed 5 2022-02-16 Reported ~ 2022-02-18\nResults: one likely pathogenic variant and one variant of uncertain clinical signifi- cance detected:\nSummary of Results: Gene Exon Base Amino zygosity Tnterpretation Acid RPST5 C33766>C p.Val126Leu heterozygous| Likely pathogenic RPST5 C.75G>T p.Leu25= heterozygous Variant Of uncer- tain clinical signifi- cance\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2022-02-14\nNote this is @ draft dataset\nGenes Analyzed: 8 total PREX2, FANCE , RPS15, RADSO, NUP98, CHD4, KDM3B, LPP;\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2022-02-14\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample. Variant 1 of 2 RPS15 C.376G7C p.Vall26Leu ) The .3766>C variant occurs at position 126 and is located in exon of the RPS15 gene, within chromosome chr19 It causes an amino acid substitution, which replaces valine with leucine ClinVar and other genomic databases report the RPST5 c.3766>C variant aS clinically relevant based on aggregated evidence. This variant is considered Iikely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVO01282991). Supporting studies and case reports can be found in the scientific Iiterature. Relevant PubMed references include: 416561588, 585889599 , 797850034, 605887806, 653024184 In accordance with existing evidence, this variant is therefore classified as a likely pathogenic variant; Variant 2 of 2 RPS15 c.75G>Tp.Leu25= ) The c.75G>T variant occurs at position 25 and is located in exon 1 of the RPSI5 gene, within chromosome chr19 It causes no amino acid change. ClinVar and other genomic databases report the RPSI5 c.75G>T variant as clinically relevant based on aggregated evidence, The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV000646780). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 762264137,746702385, 340372940, 694047658, 650535142, 896706138, 233265873 According to ClinVar, the evi- dence collected to date is insufficient to firmly establish the clinical significance of this vari- ant, therefore it is classified as a variant of uncertain clinical significance\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis; Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2022-02-14\nNote this is @ draft dataset\ntionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context, Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events; Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute). Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogeneinterference, such as PMS2 ,_ were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 5Ox, The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMG/AMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory. Limitations include reduced sensitivity in regions with pseudogenes (e.g., PMSZ , CHEK2) , and inability to de- tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism; PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-02-14\",\n  \"date_received\": \"2022-02-16\",\n  \"date_verified\": \"2022-02-18\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"PREX2\": {\n      \"gene_symbol\": \"PREX2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FANCE\": {\n      \"gene_symbol\": \"FANCE\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RPS15\": {\n      \"gene_symbol\": \"RPS15\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RAD50\": {\n      \"gene_symbol\": \"RAD50\",\n      \"refseq_mrna\": \"\"\n    },\n    \"NUP98\": {\n      \"gene_symbol\": \"NUP98\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CHD4\": {\n      \"gene_symbol\": \"CHD4\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KDM3B\": {\n      \"gene_symbol\": \"KDM3B\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LPP\": {\n      \"gene_symbol\": \"LPP\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"8\",\n  \"sample_type\": \"ctDNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"RPS15\",\n      \"variant_id\": \"VCV001282991\",\n      \"chromosome\": \"chr19\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.376G>C\",\n      \"hgvsp\": \"p.Val126Leu\",\n      \"transcript_id\": \"NM_001018.5\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    },\n    {\n      \"gene_symbol\": \"RPS15\",\n      \"variant_id\": \"VCV000646780\",\n      \"chromosome\": \"chr19\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.75G>T\",\n      \"hgvsp\": \"p.Leu25=\",\n      \"transcript_id\": \"NM_001018.5\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2023-01-25\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Amplified DNA Type of analysis: Karyotyping Referral Reason: Clinical Referring Physician: Dates Collected ~ 2023-01-25 Assessed 5 2023-01-26 Reported ~ 2023-01-26\nResults: one likely pathogenic vari- ant and one pathogenic variant detected,\nSummary of Results: Gene Exon Base Amino zygosity ` Interpretation Acid NACA 4 c.17OOC>T p.Pro567Leu heterozygous Pathogenic CHD3 C.522QA>C p Arg 1743Ser homozygous Likely pathogenic\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2023-01-25\nNote this is @ draft dataset\nGenes Analyzed: 13 total NPAPI, ATIC , ZMYND8, ETV6, NACA, HLA-A, PCDHGB3 , FANCG , CHD3, BCLZLI, H3F3C , DDXIO, ZBTB16,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2023-01-25\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: one likely pathogenic variant and one pathogenic variant were detected in the sample. Variant 1 of 2 NACA c.IZO0C>T p.Pro567Leu ) The c.1ZOOC>T variant occurs at position 567 and is located in exon 4 of the NACA gene , within chromosome chr12 It causes an amino acid substitution, which replaces proline with leucine ClinVar and other genomic databases report the NACA c.1700C>T variant aS clinically relevant based on aggregated evidence. This variant is classified as pathogenic, It is strongly associated with disease causation and has been reported in multiple affected individuals and functional studies The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession; VCV006456872). Supporting studies and case reports can be found in the scientific Iiterature. Relevant PubMed references include: 224925972,468822968 , 428645924, 976232863, 608757553, 443579659 In accordance with existing evidence, this variant is therefore classified as a pathogenic variant; Variant 2 of 2 CHD3 c.5229A>C p.Arg1743Ser ) The .5229A>C variant occurs at position 1743 and is located in exon 1 of the CHD3 gene, within chromosome chr17 It causes an amino acid substitution, which replaces arginine with serine ClinVar and other genomic databases report the CHD3 ,5229A>C variant as clinically relevant based on aggregated evidence. This variant is considered likely pathogenic  It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals; The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVO00206210). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 496462711,937235352 , 963755551, 142054777,498092124, 480154567, 892995022, 715793274 In accordance with existing evidence , this variant is therefore classified as a likely pathogenic variant;\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis; Targeted therapies should be evaluated based on these molecular findings;  Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations. However; the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2023-01-25\nNote this is @ draft dataset\nFurther germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan. Further genetic testing may be required and completed at a physician's discretion; Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes.   Target enrichment waS performed using hybrid capture technology (Twist Bioscience) , followed by paired-end sequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogene interference, such as PMS2 , were validated with long-range PCR and Sanger sequencing  The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 5Ox, The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%. Only variants classified as pathogenic , likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMG/AMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g.> PMS2 , CHEK2), and inability to de- tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism. PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2023-01-25\",\n  \"date_received\": \"2023-01-26\",\n  \"date_verified\": \"2023-01-26\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"NPAP1\": {\n      \"gene_symbol\": \"NPAP1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ATIC\": {\n      \"gene_symbol\": \"ATIC\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ZMYND8\": {\n      \"gene_symbol\": \"ZMYND8\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ETV6\": {\n      \"gene_symbol\": \"ETV6\",\n      \"refseq_mrna\": \"\"\n    },\n    \"NACA\": {\n      \"gene_symbol\": \"NACA\",\n      \"refseq_mrna\": \"\"\n    },\n    \"HLA-A\": {\n      \"gene_symbol\": \"HLA-A\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PCDHGB3\": {\n      \"gene_symbol\": \"PCDHGB3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FANCG\": {\n      \"gene_symbol\": \"FANCG\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CHD3\": {\n      \"gene_symbol\": \"CHD3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"BCL2L1\": {\n      \"gene_symbol\": \"BCL2L1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"H3F3C\": {\n      \"gene_symbol\": \"H3F3C\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DDX10\": {\n      \"gene_symbol\": \"DDX10\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ZBTB16\": {\n      \"gene_symbol\": \"ZBTB16\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"13\",\n  \"sample_type\": \"Amplified DNA\",\n  \"analysis_type\": \"Karyotyping\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"NACA\",\n      \"variant_id\": \"VCV006456872\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.1700C>T\",\n      \"hgvsp\": \"p.Pro567Leu\",\n      \"transcript_id\": \"NM_001365896.1\",\n      \"exon\": \"4\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    },\n    {\n      \"gene_symbol\": \"CHD3\",\n      \"variant_id\": \"VCV000206210\",\n      \"chromosome\": \"chr17\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.5229A>C\",\n      \"hgvsp\": \"p.Arg1743Ser\",\n      \"transcript_id\": \"NM_001005273.3\",\n      \"exon\": \"1\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Windsor Regional Hospital (Windsor)\nProcedure Date 2023-01-25\nAccession Date 2023-01-26\nReport Date 2023-01-26\nReport Details\nGenome Reference GRCh37 Sequencing Range Targeted variant testing, Karyotyping\nReferral Reason Clinical\nAnalysis Location Sinai Health System (Toronto) Table of findings: Gene Information Interpretation NACA 4 c.17OOC>T pPro567Leu heterozy- Pathogenic  gous CHD3 C.5229A>C pArg]743Ser homozy- Likely pathogenic gous\nSummary: one likely pathogenic variant and one pathogenic variant de- tected, The details regarding the specific mutations are in- cluded below,\nMRN:\nDate: 2023-01-25\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: one Iikely pathogenic variant and one pathogenic variant were detected in the sample.\nVariant 1 of 2\nGene NACA\nVariant c.IZOOC>T\nAmino\nZygosity heterozygous\np.Pro567Leu\nPathogenic\nThe 9.567 14004C>Tvariant occurs in chromosome chr12 within the NACA gene, and it causes c,1700C>T= change at position 567 in exon 4 causing the mutation p.Pro567Leu This mutation has been identified in 31 families. It has a population frequency of 7.73e-04 (360 alleles in 466005 total alleles tested), indicating it is a relatively common variant in the general population; It causes an amino acid substitution, which replaces proline with leucine ClinVar and other genomic databases report the NACA c.170OC>T variant as clinically relevant based on aggregated evidence. This variant is deemed pathogenic, It has & strong association with disease and has been documented in multiple cases, supported by functional evidence. The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCV006456872). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMed references include: 178371233, 367852573,468513941, 565650692\nMRN:\nDate: 2023-01-25\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence , this variant is therefore classified aS & pathogenic variant;\nVariant 2 of 2\nGene CHD3\nVariant C.5229A>C\nAmino\nZygosity homozygous\npArg1743Ser\nLikely pathogenic\nThe g.7890024A>C variant occurs In chromosome chr]7 within the CHD3 gene _ and it causes C.5229A>C change at position 1743 in exon 1 causing the mu- tation p.Arg1 743Ser This mutation has been identified in 30 families, It has a population frequency of 4.52e-05 (22 alleles in 486975 total alleles tested) , indi- cating it is a relatively common variant in the general population: It causes an amino acid substitution, which replaces arginine with serine ClinVar and other genomic databases report the CHD3 c.5229A>C variant as clinically relevant based on aggregated evidence. This variant is classified as Iikely pathogenic; It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals. The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVO00206210). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 134985882, 818232958, 242414597\nMRN:\nDate: 2023-01-25\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variantis therefore classified as a likely pathogenic variant; Test Details:\nGenes Analyzed and mRNA sequence (NM_): NPAPI and NM_018958.3. ATIC and NM_004044.7. ZMYND8 and NM_001281775.3. ETV6 and NM_001987.5. NACA and NM_001365896.1, HLA-AandNM_002116.8, PCDHGB3 and NM_018924.5, FANCG and NM_004629.2. CHD3 and NM_001005273.3. BCLZLI and NM 138578,3, H3F3C and NM_001013699.2, DDXIOand NM_004398.4, ZBTBI6and NM_006006.6, 13 total genes tested:\nF' Recommendations A precision oncology approach is advised, These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment; PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care: Additional testing may be pursued at the physician's discre- tion;\nMethodology Amplified DNA was sequenced with Targeted variant testing and was analyzed using Karyotyping covering all coding exons and adjacent intronic regions Tar- get enrichment was performed with hybrid capture (Twist Bioscience), followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA- MEM, and variants called with GATK. Annotation was performed in VarSeq using population databases, predictive algorithms, and ClinVar: CNVs were assessed with CNVkit and confirmed by MLPA when applicable Regions with pseudo- gene interference, such as PMS2 , were validated using long-range PCR and Sanger sequencing: Mean read depth exceeded 30Ox, with a minimum thresh- old of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >959 for exon-level CNVs. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2), and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes, or Iow-level mosaicism, PMS2 exons 1-15 are not analyzed: In- terpretations reflect current knowledge and may be updated as new evidence\nMRN:\nDate: 2023-01-25\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nemerges:\nMRN:\nDate: 2023-01-25\nPage 5\n1 Mock\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2023-01-25\nPage 6\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2023-01-25\",\n  \"date_received\": \"2023-01-26\",\n  \"date_verified\": \"2023-01-26\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Windsor Regional Hospital (Windsor)\",\n  \"testing_laboratory\": \"Sinai Health System (Toronto)\",\n  \"sequencing_scope\": \"Targeted variant testing\",\n  \"tested_genes\": {\n    \"NPAP1\": {\n      \"gene_symbol\": \"NPAP1\",\n      \"refseq_mrna\": \"NM_018958.3\"\n    },\n    \"ATIC\": {\n      \"gene_symbol\": \"ATIC\",\n      \"refseq_mrna\": \"NM_004044.7\"\n    },\n    \"ZMYND8\": {\n      \"gene_symbol\": \"ZMYND8\",\n      \"refseq_mrna\": \"NM_001281775.3\"\n    },\n    \"ETV6\": {\n      \"gene_symbol\": \"ETV6\",\n      \"refseq_mrna\": \"NM_001987.5\"\n    },\n    \"NACA\": {\n      \"gene_symbol\": \"NACA\",\n      \"refseq_mrna\": \"NM_001365896.1\"\n    },\n    \"HLA-A\": {\n      \"gene_symbol\": \"HLA-A\",\n      \"refseq_mrna\": \"NM_002116.8\"\n    },\n    \"PCDHGB3\": {\n      \"gene_symbol\": \"PCDHGB3\",\n      \"refseq_mrna\": \"NM_018924.5\"\n    },\n    \"FANCG\": {\n      \"gene_symbol\": \"FANCG\",\n      \"refseq_mrna\": \"NM_004629.2\"\n    },\n    \"CHD3\": {\n      \"gene_symbol\": \"CHD3\",\n      \"refseq_mrna\": \"NM_001005273.3\"\n    },\n    \"BCL2L1\": {\n      \"gene_symbol\": \"BCL2L1\",\n      \"refseq_mrna\": \"NM_138578.3\"\n    },\n    \"H3F3C\": {\n      \"gene_symbol\": \"H3F3C\",\n      \"refseq_mrna\": \"NM_001013699.2\"\n    },\n    \"DDX10\": {\n      \"gene_symbol\": \"DDX10\",\n      \"refseq_mrna\": \"NM_004398.4\"\n    },\n    \"ZBTB16\": {\n      \"gene_symbol\": \"ZBTB16\",\n      \"refseq_mrna\": \"NM_006006.6\"\n    }\n  },\n  \"num_tested_genes\": \"13\",\n  \"sample_type\": \"Amplified DNA\",\n  \"analysis_type\": \"Karyotyping\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"NACA\",\n      \"variant_id\": \"VCV006456872\",\n      \"chromosome\": \"chr12\",\n      \"hgvsg\": \"g.56714004C>T\",\n      \"hgvsc\": \"c.1700C>T\",\n      \"hgvsp\": \"p.Pro567Leu\",\n      \"transcript_id\": \"NM_001365896.1\",\n      \"exon\": \"4\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Pathogenic\",\n      \"mafac\": \"360\",\n      \"mafan\": \"466005\",\n      \"mafaf\": \"7.73e-04\"\n    },\n    {\n      \"gene_symbol\": \"CHD3\",\n      \"variant_id\": \"VCV000206210\",\n      \"chromosome\": \"chr17\",\n      \"hgvsg\": \"g.7890024A>C\",\n      \"hgvsc\": \"c.5229A>C\",\n      \"hgvsp\": \"p.Arg1743Ser\",\n      \"transcript_id\": \"NM_001005273.3\",\n      \"exon\": \"1\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"22\",\n      \"mafan\": \"486975\",\n      \"mafaf\": \"4.52e-05\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"GRCh37\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft MOLECULAR GENETICS LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Grand River Hospital (Kitchener)\nProcedure Date 2020-04-26\nAccession Date 2020-04-27\nReport Date 2020-04-28\nReport Details\nGenome Reference NCBI Build 36.1 Sequencing Range Gene panel, Repeat expansion analysis\nReferral Reason Research\nAnalysis Location Children's Hospital of Eastern Ontario (Ottawa) Table of findings: Gene Information Interpretation TNK2 4 C,20826>C p,Pro694= homozygous Zikely pathogenic \nSummary: One likely pathogenic variant detected:_ The details regarding the specific mutations are included below:\nMRN:\nDate: 2020-04-26\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample.\nVariant 1 of 1\nGene TNK2\nVariant C.20826>C\nAmino Zygosity p.Pro694= homozygous Likely pathogenic 6 The g.195865445G>C variant occurs in chromosome chr3 within the TNK2 gene _ and it causes ,.20826>C change at position 694 in exon 4 causing the muta- tion p.Pro694= This mutation has been identified in 46 families, It has a popu- lation frequency of 4.41e-04 (183 alleles in 415149 total alleles tested), indicat- ing it is a relatively common variant in the general population: It causes no amino acid change, ClinVar and other genomic databases report the TNK2 c.2082G>C variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic, It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVOO1482074). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMed references include: 725313603, 422485496, 168765427,348360404, 390800399, 781790764, 939311671, 911452464\nMRN:\nDate: 2020-04-26\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variantis therefore classified as a likely pathogenic variant; Test Details:\nGenes Analyzed and mRNA sequence (NM_): CNBP and NM_003418,5, FOXO3 and NM_001455.4. CDKNZC and NM_078626.3. CSMD3 and NM 198123.2. AURKA and NM_ 198435,3, NPAPI and NM_018958.3. MPO and NM_000250.2, MLLT3 and NM_004529.4. SRCAP and NM_006662.3. ICK and NM_016513.4. RADSIB and NM_133510.4. TNFRSF17 and NM_OOI192.3. TNK2 and NM_001387716.1, CTNND] and NM_001085458.2. JMJDIC and NM_032776.3. PPARG and NM_138711.6, 16 total genes tested,\nRecommendations A precision oncology approach is advised. These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre- tion;\nMethodology polyA+ RNA was sequenced with Gene panel and was analyzed using Repeat expansion analysis covering all coding exons and adjacent intronic regions Tar- get enrichment was performed with hybrid capture (Twist Bioscience) , followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA- MEM, and variants called with GATK. Annotation was performed in VarSeq using population databases, predictive algorithms, and ClinVar: CNVs were assessed with CNVkit and confirmed by MLPA when applicable; Regions with pseudo- gene interference, such as PMS2 , were validated using long-range PCR and Sanger sequencing: Mean read depth exceeded 30Ox , with a minimum thresh- old of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs  Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868) . Limitations This test waS developed and validated in a certified clinical laboratory; Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes, or low-level mosaicism; PMS2 exons 11-15 are not analyzed. In-\nMRN:\nDate: 2020-04-26\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: info@och,on.ca Diagnostics phone: 437-416-6470 416-456-7890 terpretations reflect current knowledge and may be updated as new evidence emerges; 1 Mock\nMRN:\nDate: 2020-04-26\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2020-04-26\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2020-04-26\",\n  \"date_received\": \"2020-04-27\",\n  \"date_verified\": \"2020-04-28\",\n  \"report_type\": \"Molecular Genetics\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"Grand River Hospital (Kitchener)\",\n  \"testing_laboratory\": \"Children's Hospital of Eastern Ontario (Ottawa)\",\n  \"sequencing_scope\": \"Gene panel\",\n  \"tested_genes\": {\n    \"CNBP\": {\n      \"gene_symbol\": \"CNBP\",\n      \"refseq_mrna\": \"NM_003418.5\"\n    },\n    \"FOXO3\": {\n      \"gene_symbol\": \"FOXO3\",\n      \"refseq_mrna\": \"NM_001455.4\"\n    },\n    \"CDKN2C\": {\n      \"gene_symbol\": \"CDKN2C\",\n      \"refseq_mrna\": \"NM_078626.3\"\n    },\n    \"CSMD3\": {\n      \"gene_symbol\": \"CSMD3\",\n      \"refseq_mrna\": \"NM_198123.2\"\n    },\n    \"AURKA\": {\n      \"gene_symbol\": \"AURKA\",\n      \"refseq_mrna\": \"NM_198435.3\"\n    },\n    \"NPAP1\": {\n      \"gene_symbol\": \"NPAP1\",\n      \"refseq_mrna\": \"NM_018958.3\"\n    },\n    \"MPO\": {\n      \"gene_symbol\": \"MPO\",\n      \"refseq_mrna\": \"NM_000250.2\"\n    },\n    \"MLLT3\": {\n      \"gene_symbol\": \"MLLT3\",\n      \"refseq_mrna\": \"NM_004529.4\"\n    },\n    \"SRCAP\": {\n      \"gene_symbol\": \"SRCAP\",\n      \"refseq_mrna\": \"NM_006662.3\"\n    },\n    \"ICK\": {\n      \"gene_symbol\": \"ICK\",\n      \"refseq_mrna\": \"NM_016513.4\"\n    },\n    \"RAD51B\": {\n      \"gene_symbol\": \"RAD51B\",\n      \"refseq_mrna\": \"NM_133510.4\"\n    },\n    \"TNFRSF17\": {\n      \"gene_symbol\": \"TNFRSF17\",\n      \"refseq_mrna\": \"NM_001192.3\"\n    },\n    \"TNK2\": {\n      \"gene_symbol\": \"TNK2\",\n      \"refseq_mrna\": \"NM_001387716.1\"\n    },\n    \"CTNND1\": {\n      \"gene_symbol\": \"CTNND1\",\n      \"refseq_mrna\": \"NM_001085458.2\"\n    },\n    \"JMJD1C\": {\n      \"gene_symbol\": \"JMJD1C\",\n      \"refseq_mrna\": \"NM_032776.3\"\n    },\n    \"PPARG\": {\n      \"gene_symbol\": \"PPARG\",\n      \"refseq_mrna\": \"NM_138711.6\"\n    }\n  },\n  \"num_tested_genes\": \"16\",\n  \"sample_type\": \"polyA+ RNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"TNK2\",\n      \"variant_id\": \"VCV001482074\",\n      \"chromosome\": \"chr3\",\n      \"hgvsg\": \"g.195865445G>C\",\n      \"hgvsc\": \"c.2082G>C\",\n      \"hgvsp\": \"p.Pro694=\",\n      \"transcript_id\": \"NM_001387716.1\",\n      \"exon\": \"4\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"183\",\n      \"mafan\": \"415149\",\n      \"mafaf\": \"4.41e-04\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"NCBI Build 36.1\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2020-04-26\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: polyA+ RNA Type of analysis: Repeat expansion analysis Referral Reason: Research Referring Physician: Dates Collected ~ 2020-04-26 Assessed ~ 2020-04-27 Reported ~ 2020-04-28\nResults: One Iikely pathogenic variant detected:\nSummary of Results: Gene Exon Base \" Amino Acid TNK2 C.2082G>C p.Pro694=\nZygosity\nInterpretation  \nhomozygous Likely pathogenic\nGenes Analyzed: 16 total CNBP; FOXO3, CDKNZC , CSMD3, AURKA, NPAPI, MPO, MLLT3 , SR- CAP, ICK, RADSIB, TNFRSF] 7, TNK2, CTNNDI, JMJDIC , PPARG,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2020-04-26\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample. Variant 1 of 1 TNK2 C.2082G>C p.Pro694= ) The .2082G>C variant occurs at position 694 and is located in exon 4 of the TNK2 gene , within chromosome chr3 It causes no amino acid change. ClinVar and other genomic databases report the TNKZ .2082G>C variant as clinically relevant based on aggregated evidence, This variant is considered likely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVOO1482074). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 661870669, 924455047, 682417977,699513409 In accordance with existing evidence , this variant is therefore clas sified as a likely pathogenic variant;\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis.  Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context. Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes.  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform. Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2020-04-26\nNote this is @ draft dataset\nland) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox , with a minimum depth threshold of 5Ox. The analytical sensitivity for single nucleotide variants and small indels is >o9%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g.= PMS2 , CHEK2) , and inability to de tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism, PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2020-04-26\",\n  \"date_received\": \"2020-04-27\",\n  \"date_verified\": \"2020-04-28\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"CNBP\": {\n      \"gene_symbol\": \"CNBP\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FOXO3\": {\n      \"gene_symbol\": \"FOXO3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CDKN2C\": {\n      \"gene_symbol\": \"CDKN2C\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CSMD3\": {\n      \"gene_symbol\": \"CSMD3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"AURKA\": {\n      \"gene_symbol\": \"AURKA\",\n      \"refseq_mrna\": \"\"\n    },\n    \"NPAP1\": {\n      \"gene_symbol\": \"NPAP1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MPO\": {\n      \"gene_symbol\": \"MPO\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MLLT3\": {\n      \"gene_symbol\": \"MLLT3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SRCAP\": {\n      \"gene_symbol\": \"SRCAP\",\n      \"refseq_mrna\": \"\"\n    },\n    \"ICK\": {\n      \"gene_symbol\": \"ICK\",\n      \"refseq_mrna\": \"\"\n    },\n    \"RAD51B\": {\n      \"gene_symbol\": \"RAD51B\",\n      \"refseq_mrna\": \"\"\n    },\n    \"TNFRSF17\": {\n      \"gene_symbol\": \"TNFRSF17\",\n      \"refseq_mrna\": \"\"\n    },\n    \"TNK2\": {\n      \"gene_symbol\": \"TNK2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CTNND1\": {\n      \"gene_symbol\": \"CTNND1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"JMJD1C\": {\n      \"gene_symbol\": \"JMJD1C\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PPARG\": {\n      \"gene_symbol\": \"PPARG\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"16\",\n  \"sample_type\": \"polyA+ RNA\",\n  \"analysis_type\": \"Repeat expansion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"TNK2\",\n      \"variant_id\": \"VCV001482074\",\n      \"chromosome\": \"chr3\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.2082G>C\",\n      \"hgvsp\": \"p.Pro694=\",\n      \"transcript_id\": \"NM_001387716.1\",\n      \"exon\": \"4\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2022-05-02\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Other RNA fractions Type of analysis: Fusion analysis Referral Reason: Research Referring Physician: Dates Collected ~ 2022-05-02 Assessed 5 2022-05-03 Reported ~ 2022-05-04\nResults: one likely pathogenic variant and one variant of uncertain clinical signifi- cance detected:\nSummary of Results: Gene Exon Base Amino zygosity Tnterpretation Acid PICALM 20 C.I44C>T p.Cys48= heterozygous| Likely pathogenic PICALM 20 C.657G>T p.Leu21 9Phe heterozygous Variant Of uncer- tain clinical signifi- cance\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2022-05-02\nNote this is @ draft dataset\nGenes Analyzed: 5 total ASXL2, SOCSI, DST, PICALM, KDMSC ,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2022-05-02\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample. Variant 1 of 2 PICALM c.IAAC>Tp.Cys48= ) The c.144C>T variant occurs at position 48 and is located in exon 20 of the PICALM gene, within chromosome chr] 1 It causes no amino acid change: ClinVar and other genomic databases report the PICALM c.144C>Tvariant as clinically relevant based on aggregated evidence, This variant is considered likely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVO00806831). Supporting studies and case reports can be found in the scientific literature, Relevant PubMed references include: 834379057,438943985, 120239815, 315986078,277471975, 354826374,929404599, 579043254 In accordance with existing evidence, this variant is therefore classified as a likely pathogenic variant Variant 2 of 2 PICALM c.657G>T p.Leu219Phe ) The c.657G>Tvariant occurs at position 219 and is located in exon 20 of the PICALM gene , within chromosome chr] 1 It causes an amino acid substitution, which replaces leucine with phenylalanine ClinVar and other genomic databases report the PICALM c.6576>T variant as clinically relevant based on aggregated evidence. The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VcV009908810). Supporting studies and case reports can be found in the scientific literature. Relevant PubMedreferences include: 367041589,538697525, 274495615, 143129726, 153210451, 444080529, 322753896 According to ClinVar; the ev- idence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis; Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2022-05-02\nNote this is @ draft dataset\ntionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context, Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events; Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform: Sequencing reads were aligned to the GRCh37 /hg19human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute). Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar; Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogeneinterference, such as PMS2 ,_ were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox, with a minimum depth threshold of 5Ox, The analytical sensitivity for single nucleotide variants and small indels is >99%, and for exon-level CNVs, >95%. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMG/AMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory. Limitations include reduced sensitivity in regions with pseudogenes (e.g., PMSZ , CHEK2) , and inability to de- tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism; PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-05-02\",\n  \"date_received\": \"2022-05-03\",\n  \"date_verified\": \"2022-05-04\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"ASXL2\": {\n      \"gene_symbol\": \"ASXL2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SOCS1\": {\n      \"gene_symbol\": \"SOCS1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DST\": {\n      \"gene_symbol\": \"DST\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PICALM\": {\n      \"gene_symbol\": \"PICALM\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KDM5C\": {\n      \"gene_symbol\": \"KDM5C\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"5\",\n  \"sample_type\": \"Other RNA fractions\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"PICALM\",\n      \"variant_id\": \"VCV000806831\",\n      \"chromosome\": \"chr11\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.144C>T\",\n      \"hgvsp\": \"p.Cys48=\",\n      \"transcript_id\": \"NM_007166.4\",\n      \"exon\": \"20\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    },\n    {\n      \"gene_symbol\": \"PICALM\",\n      \"variant_id\": \"VCV009908810\",\n      \"chromosome\": \"chr11\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.657G>T\",\n      \"hgvsp\": \"p.Leu219Phe\",\n      \"transcript_id\": \"NM_007166.4\",\n      \"exon\": \"20\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Hamilton Health Sciences (Hamilton)\nProcedure Date 2022-05-02\nAccession Date 2022-05-03\nReport Date 2022-05-04\nReport Details\nGenome Reference NCBI Build 35 Sequencing Range Whole exome sequencing (WES) , Fusion analysis\nReferral Reason Research\nAnalysis Location Sinai Health System (Toronto) Table of findings: Gene Information Interpretation PICALM 20 C, AACST p Cys48= heterozygous Zikely pathogenic  PICALM 20 c.657G>1 p.Leu2]9Phe heterozy- Variant of uncertain goUs clinical significance\nSummary: one likely pathogenic variant and one variant of uncertain clin- ical significance detected. The details regarding the specific mutations are included below.\nMRN:\nDate: 2022-05-02\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: one likely pathogenic variant and one variant of uncertain clinical significance were detected in the sample \nVariant 1 of 2\nGene PICALM\nVariant c.]44C>T\nAmino Zygosity p.Cys48= heterozygous Likely pathogenic 8 The g.85957318C>T variant occurs in chromosome chr] 1 within the PICALM gene, and it causes c.1AAC>T change at position 48 in exon 20 causing the mutation p.Cys48= This mutation has been identified in 47 families. It has a population frequency of 0.00e+00 (0 alleles in 510480 total alleles tested) , indi- cating it is a very rare variantin the general population: It causes no amino acid change ClinVar and other genomic databases report the PICALM c.I44C>T variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCV000806831 ). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMed references include: 580652584, 590606130,759605379,814379277, 159129513, 728092361, 736206477,773223498\nMRN:\nDate: 2022-05-02\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variant is therefore classified as a likely pathogenic variant;\nVariant 2 of 2\nGene PICALM\nVariant C.657G>T\nAmino\nZygosity heterozygous\np.Leu219Phe\nVariant of uncertain clinical significance\nThe 9.85957831G>T variant occurs in chromosome chr] 1 within the PICALM gene, and it causes c.657G>T change at position 219 in exon 20 causing the mutation p.Leu2]9Phe This mutation has been identified in 41 families  It has population frequency of 1.50e-03 (827 alleles in 550941 total alleles tested), indicating it is a very rare variant in the general population: It causes an amino acid substitution, which replaces leucine with phenylalanine ClinVar and other genomic databases report the PICALM c.6576>T variant as clinically relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood; At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV009908810). Supporting studies and case reports can be found in the scientific literature: Rel- evant PubMedreferences include: 976064860,925905501,899578133, 528424916, 179155164, 100109846, 640902895, 702166321\nMRN:\nDate: 2022-05-02\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): ASXL2 and NM_018263.6. SOCS] and NM_003745.2, DST and NM_001374734,1, PICALM and NM_007166,4, KDMSC and NM_004187.5. 5 total genes tested;\nRecommendations A precision oncology approach is advised: These mutations are known onco- genic drivers, Iinked to constitutive pathway activation: Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre_ tion;\nMethodology Other RNA fractions was sequenced with Whole exome sequencing (WES) and was analyzed using Fusion analysis covering all coding exons and adjacent intronic regions; Target enrichment was performed with hybrid capture (Twist Bioscience) , followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK , Annotation waS per- formed in VarSeq using population databases, predictive algorithms, and Clin- Var; CNVs were assessed with CNVkit and confirmed by MLPA when applica- ble. Regions with pseudogene interference, such as PMS2 , were validated using long-range PCR and Sanger sequencing: Mean read depth exceeded 30Ox , with a minimum threshold of 5Ox. Analytical sensitivity is >99% for SNVs/indels and >95% for exon-level CNVs. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMG/AMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , andinability to detect certain structural variants (e.g., MSHZ inversions) , deepin- tronic changes, or low-level mosaicism. PMS2 exons 11-15 are not analyzed. In- terpretations reflect current knowledge and may be updated as new evidence emerges;\nMRN:\nDate: 2022-05-02\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2022-05-02\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2022-05-02\",\n  \"date_received\": \"2022-05-03\",\n  \"date_verified\": \"2022-05-04\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Research\",\n  \"ordering_clinic\": \"Hamilton Health Sciences (Hamilton)\",\n  \"testing_laboratory\": \"Sinai Health System (Toronto)\",\n  \"sequencing_scope\": \"Whole exome sequencing (WES)\",\n  \"tested_genes\": {\n    \"ASXL2\": {\n      \"gene_symbol\": \"ASXL2\",\n      \"refseq_mrna\": \"NM_018263.6\"\n    },\n    \"SOCS1\": {\n      \"gene_symbol\": \"SOCS1\",\n      \"refseq_mrna\": \"NM_003745.2\"\n    },\n    \"DST\": {\n      \"gene_symbol\": \"DST\",\n      \"refseq_mrna\": \"NM_001374734.1\"\n    },\n    \"PICALM\": {\n      \"gene_symbol\": \"PICALM\",\n      \"refseq_mrna\": \"NM_007166.4\"\n    },\n    \"KDM5C\": {\n      \"gene_symbol\": \"KDM5C\",\n      \"refseq_mrna\": \"NM_004187.5\"\n    }\n  },\n  \"num_tested_genes\": \"5\",\n  \"sample_type\": \"Other RNA fractions\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"PICALM\",\n      \"variant_id\": \"VCV000806831\",\n      \"chromosome\": \"chr11\",\n      \"hgvsg\": \"g.85957318C>T\",\n      \"hgvsc\": \"c.144C>T\",\n      \"hgvsp\": \"p.Cys48=\",\n      \"transcript_id\": \"NM_007166.4\",\n      \"exon\": \"20\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"0\",\n      \"mafan\": \"510480\",\n      \"mafaf\": \"0.00e+00\"\n    },\n    {\n      \"gene_symbol\": \"PICALM\",\n      \"variant_id\": \"VCV009908810\",\n      \"chromosome\": \"chr11\",\n      \"hgvsg\": \"g.85957831G>T\",\n      \"hgvsc\": \"c.657G>T\",\n      \"hgvsp\": \"p.Leu219Phe\",\n      \"transcript_id\": \"NM_007166.4\",\n      \"exon\": \"20\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"827\",\n      \"mafan\": \"550941\",\n      \"mafaf\": \"1.50e-03\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"NCBI Build 35\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2021-04-27\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: Total RNA Type of analysis: Fusion analysis Referral Reason: Clinical Referring Physician: Dates Collected ~ 2021-04-27 Assessed _ 2021-04-28 Reported ~ 2021-04-29\nResults: Two variants of uncertain clinical significance de- tected;\nSummary of Results:\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2021-04-27\nNote this is @ draft dataset\nGene\nExon\nBase\nAmino Acid p.Arg24=\nzygosity\"\nInterpretation\nHISTIHAJ\nC.72C>A\nhomozygous Variant Of uncer- tain clinical signifi- cance C.13233G> pATgAATTSer heterozygous Variant Of uncer- tain clinical signifi- cance\nDYNCTHT\nGenes Analyzed: 10 total FES, GAS7, PTPRT, SDHD, KEAPI, CARS, DYNCIHI, HISTIHAJ , BRD3 , FGFRI ,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2021-04-27\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows:   Two variants of uncertain clinical signifi- cance were detected in the sample. Variant 1 of 2 HISTIHAJ c.72C>A pArg2a-= ) The c.72C>A variant occurs at position 24 and is located in exon 4 of the HISTIHAJ gene , within chromosome chr6 It causes no amino acid change ClinVar and other genomic databases report the HISTIHAJ c.72C>A variant as clinically relevant based on aggregated evidence, The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease_ The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint: This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV009430632). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 338351693,321321100, 645257097, 317946550, 522538536, 277555969, 729215782 According to ClinVar, the ev- idence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Variant 2 of 2 DYNCIHI ( c.13233G>C pArg44] 1Ser ) The c.132336>C variant occurs at position 4411 and is located in exon 7 of the DYNCIHI gene, within chromosome chr14 , It causes an amino acidsubstitution, which replaces argi- nine with serine ClinVar and other genomic databases report the DYNCIHI c.132336>C variant as clinically relevant based on aggregated evidence  The clinical relevance of this variant remains unclear; Currently, there is insufficient evidence to confirm or refute its role in disease. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCVOOO711307). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 392937238,444135964, 311921465,637235031 According to ClinVar; the evidence collected to date is insufficient to firmly establish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance\nRecommendations We recommend a precision oncology approach; These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis; Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\nOCH\nMRN:\nDate Collected: 2021-04-27\nNote this is @ draft dataset\ncaused by these mutations; However; the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context: Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events, Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes;  Target enrichment waS performed using hybrid capture technology (Twst Bioscience) , followed by paired-endsequencing on the Illumina NextSeq platform. Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo rating population frequency databases, in silico prediction tools, and ClinVar Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol- land) when applicable. Regions with known pseudogene interference, such as PMS2 , were validated with long-range PCR and Sanger sequencing; The average read depth across all targeted regions exceeded 30Ox , with a minimum depth threshold of 50x, The analytical sensitivity for single nucleotide variants and small indels is >9%, and for exon-level CNVs, >959. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (exg: PMS2 , CHEK2) , and inability to de- tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or Iow-level mosaicism. PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time:\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 4\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2021-04-27\",\n  \"date_received\": \"2021-04-28\",\n  \"date_verified\": \"2021-04-29\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"FES\": {\n      \"gene_symbol\": \"FES\",\n      \"refseq_mrna\": \"\"\n    },\n    \"GAS7\": {\n      \"gene_symbol\": \"GAS7\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PTPRT\": {\n      \"gene_symbol\": \"PTPRT\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SDHD\": {\n      \"gene_symbol\": \"SDHD\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KEAP1\": {\n      \"gene_symbol\": \"KEAP1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CARS\": {\n      \"gene_symbol\": \"CARS\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DYNC1H1\": {\n      \"gene_symbol\": \"DYNC1H1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"HIST1H4J\": {\n      \"gene_symbol\": \"HIST1H4J\",\n      \"refseq_mrna\": \"\"\n    },\n    \"BRD3\": {\n      \"gene_symbol\": \"BRD3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"FGFR1\": {\n      \"gene_symbol\": \"FGFR1\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"10\",\n  \"sample_type\": \"Total RNA\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"HIST1H4J\",\n      \"variant_id\": \"VCV009430632\",\n      \"chromosome\": \"chr6\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.72C>A\",\n      \"hgvsp\": \"p.Arg24=\",\n      \"transcript_id\": \"NM_021968.3\",\n      \"exon\": \"4\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    },\n    {\n      \"gene_symbol\": \"DYNC1H1\",\n      \"variant_id\": \"VCV000711307\",\n      \"chromosome\": \"chr14\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.13233G>C\",\n      \"hgvsp\": \"p.Arg4411Ser\",\n      \"transcript_id\": \"NM_001376.5\",\n      \"exon\": \"7\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Peterborough Regional Health Centre (Peterborough)\nProcedure Date 2021-04-27\nAccession Date 2021-04-28\nReport Date 2021-04-29\nReport Details\nGenome Reference NCBI Build 35 Sequencing Range Gene panel, Fusion analysis\nReferral Reason Clinical\nAnalysis Location London Health Sciences Centre (London) Table of findings: Gene Information Interpretation HISTTHAJ 4c.72C>A p.Arg24= homozygous Variant of uncertain clinical significance DYNCIHJ 7 c.132336>C p.Arg441 ]Ser heterozy- Variant of uncertain goUs clinical significance\nSummary: Two variants of uncertain clinical significance detected;. The de- tails regarding the specific mutations are included below:\nMRN:\nDate: 2021-04-27\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: Two variants of uncertain clinical significance were detected in the sample:\nVariant 1 of 2\nGene HISTIHAJ\nVariant c.72C>A\nAmino Zygosity p.Arg24= homozygous Variant of uncertain clinical significance ( The 9.27824196C>A variant occurs in chromosome chr6 within the HISTIHAJ gene, and it causes c.72C>A change at position 24 in exon 4 causing the mutation p.Arg24= This mutation has been identified in 35 families. It has a population frequency of 6.76e-04 (239 alleles in 353778 total alleles tested), indi- cating it is a relatively common variant in the general population; It causes no amino acid change. ClinVar and other genomic databases report the HISTIHAJ c.72C>A variant as clinically relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood: At present , available data is insufficient to confirm its role in disease_ The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCV0O9430632). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMed references include: 647948671,869785357,510811097,333868770, 385918955, 930017325, 753929762\nMRN:\nDate: 2021-04-27\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance\nVariant 2 of 2\nGene DYNCIHI\nVariant\nAmino\nZygosity heterozygous\nc.132336>C\np.Arg441 ISer\nVariant of uncertain clinical significance\nThe g.101977805G>C variant occurs in chromosome chr14 within the DYNCIHI gene, and it causes c.132336>C change at position 4411 in exon 7 causing the mutation p.Arg441 ]Ser This mutation has been identified in 39 families. It has a population frequency of 0.0Oe+O0 (0 alleles in 625841 total alleles tested) _ indicating it is a very rare variant in the general population: It causes an amino acid substitution, which replaces arginine with serine ClinVar and other ge nomic databases report the DYNCIHI c.132336>C variant as clinically relevant based on aggregated evidence. The clinical implications of this variant are not yet fully understood; At present , available data is insufficient to confirm its role in disease. The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is not currently strongly implicated in specific diseases according to ClinVar records (VCV accession: VCVOOO7 11307) . Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 102492766, 489263050,415155354\nMRN:\nDate: 2021-04-27\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 According to ClinVar; the evidence collected to date is insufficient to firmly es- tablish the clinical significance of this variant, therefore it is classified as a variant of uncertain clinical significance Test Details:\nGenes Analyzed and mRNA sequence (NM_): FES and NM_002005.4. GASZ and NM_201433.2. PTPRT and NM_007050.6, SDHD and NM_003002.4, KEAPI and NM_203500.2, CARSand NM_OO1194997.1, DYNCIHI and NM_001376,5, HISTIHAJ and NM_021968.3. BRD3 and NM_007371.4, FGFRI and NM_023110.3, 10 total genes tested;\nRecommendations C' A precision oncology approach is advised, These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment; PI3K inhibitors could be explored in trials for PIK3CA-mutated cases. Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care: Additional testing may be pursued at the physician's discre- tion;\nMethodology Total RNA was sequenced with Gene panel and was analyzed using Fusion analysis covering all coding exons and adjacent intronic regions Target en- richment was performed with hybrid capture (Twist Bioscience) , followed by I1- lumina NextSeq sequencing: Reads were aligned to GRCh37 using BWA-MEM, and variants called with GATK. Annotation was performed in VarSeq using pop ulation databases, predictive algorithms, and ClinVar CNVs were assessed with CNVkit and confirmed by MLPA when applicable; Regions with pseudogene in- terference , such as PMS2 , were validated using long-range PCR and Sanger se- quencing: Mean read depth exceeded 30Ox, with a minimum threshold of 5Ox. Analytical sensitivity is >99% for SNVs /indels and >95% for exon-level CNVs, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain sig- nificance (VUS) are reported, per ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMSZ , CHEK2) - and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes , or low-level mosaicism; PMS2 exons 11-15 are not analyzed, In- terpretations reflect current knowledge and may be updated as new evidence emerges:\nMRN:\nDate: 2021-04-27\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2021-04-27\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2021-04-27\",\n  \"date_received\": \"2021-04-28\",\n  \"date_verified\": \"2021-04-29\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Peterborough Regional Health Centre (Peterborough)\",\n  \"testing_laboratory\": \"London Health Sciences Centre (London)\",\n  \"sequencing_scope\": \"Gene panel\",\n  \"tested_genes\": {\n    \"FES\": {\n      \"gene_symbol\": \"FES\",\n      \"refseq_mrna\": \"NM_002005.4\"\n    },\n    \"GAS7\": {\n      \"gene_symbol\": \"GAS7\",\n      \"refseq_mrna\": \"NM_201433.2\"\n    },\n    \"PTPRT\": {\n      \"gene_symbol\": \"PTPRT\",\n      \"refseq_mrna\": \"NM_007050.6\"\n    },\n    \"SDHD\": {\n      \"gene_symbol\": \"SDHD\",\n      \"refseq_mrna\": \"NM_003002.4\"\n    },\n    \"KEAP1\": {\n      \"gene_symbol\": \"KEAP1\",\n      \"refseq_mrna\": \"NM_203500.2\"\n    },\n    \"CARS\": {\n      \"gene_symbol\": \"CARS\",\n      \"refseq_mrna\": \"NM_001194997.1\"\n    },\n    \"DYNC1H1\": {\n      \"gene_symbol\": \"DYNC1H1\",\n      \"refseq_mrna\": \"NM_001376.5\"\n    },\n    \"HIST1H4J\": {\n      \"gene_symbol\": \"HIST1H4J\",\n      \"refseq_mrna\": \"NM_021968.3\"\n    },\n    \"BRD3\": {\n      \"gene_symbol\": \"BRD3\",\n      \"refseq_mrna\": \"NM_007371.4\"\n    },\n    \"FGFR1\": {\n      \"gene_symbol\": \"FGFR1\",\n      \"refseq_mrna\": \"NM_023110.3\"\n    }\n  },\n  \"num_tested_genes\": \"10\",\n  \"sample_type\": \"Total RNA\",\n  \"analysis_type\": \"Fusion analysis\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"HIST1H4J\",\n      \"variant_id\": \"VCV009430632\",\n      \"chromosome\": \"chr6\",\n      \"hgvsg\": \"g.27824196C>A\",\n      \"hgvsc\": \"c.72C>A\",\n      \"hgvsp\": \"p.Arg24=\",\n      \"transcript_id\": \"NM_021968.3\",\n      \"exon\": \"4\",\n      \"zygosity\": \"homozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"239\",\n      \"mafan\": \"353778\",\n      \"mafaf\": \"6.76e-04\"\n    },\n    {\n      \"gene_symbol\": \"DYNC1H1\",\n      \"variant_id\": \"VCV000711307\",\n      \"chromosome\": \"chr14\",\n      \"hgvsg\": \"g.101977805G>C\",\n      \"hgvsc\": \"c.13233G>C\",\n      \"hgvsp\": \"p.Arg4411Ser\",\n      \"transcript_id\": \"NM_001376.5\",\n      \"exon\": \"7\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Variant of uncertain clinical significance\",\n      \"mafac\": \"0\",\n      \"mafan\": \"625841\",\n      \"mafaf\": \"0.00e+00\"\n    }\n  ],\n  \"num_variants\": \"2\",\n  \"reference_genome\": \"NCBI Build 35\"\n}\n\nEND\n\n"}
{"prompt": "OCH\nMRN:\nDate Collected: 2021-08-17\nNote this is @ draft dataset\nOntario Cancer Hospital 123 Main St, West, Toronto, ON, A4B5G9 info@och.on.ca fax: 416-456-7890 phone: 437 - 416-6470\nDivision of Tumor Sequencing and Diagnostics\nLABORATORY RESULTS\nReport electronically signed by:\nPatient Info. First Name: Redacted Last Name: DOB; Sex: Health Card: Medical Record #; Sample tested: ctDNA Type of analysis: Karyotyping Referral Reason: Clinical Referring Physician: Dates Collected ~ 2021-08-17 Assessed _ 2021-08-18 Reported ~ 2021-08-20\nResults: One Iikely pathogenic variant detected:\nSummary of Results: Gene Exon Base \" Amino Zygosity Interpretation   Acid SDHA c,1294G>T p.Val432Leu heterozygous_ Likely pathogenic\nGenes Analyzed: 18 total SDHA, PLCG2, CDKNZC , IDH2, AFFI, MYHI, BCOR, ORAA16, LIFR, SMAD4, AURKB, CDK8 , POTEF, EWSRI , LRIG3 , DEK, KDMAC , KLK2 ,\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 1\n\nOCH\nMRN:\nDate Collected: 2021-08-17\nNote this is @ draft dataset\nTest Details:\nFindings: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample. Variant 1 of 1 SDHA c.1294G>T p.Val432Leu The c.1294G>T variant occurs at position 432 and is located in exon 1 of the SDHA gene, within chromosome chr5 It causes an amino acid substitution, which replaces valine with leucine ClinVar and other genomic databases report the SDHA C.1294G>T variant aS clinically relevant based on aggregated evidence. This variant is considered Iikely pathogenic: It has been associated with deleterious effects on protein function and may contribute to disease in affected individuals. The affected nucleotide lies within a region that is highly conserved across vertebrate species, which suggests functional importance and evolutionary constraint; This variant is implicated in oncogenesis and other disease processes according to Clin- Var records (VCV accession: VCVO01370768). Supporting studies and case reports can be found in the scientific literature. Relevant PubMed references include: 192486695,374378162, 946984689 In accordance with existing evidence , this variant is therefore classified as & likely pathogenic variant;\nRecommendations We recommend a precision oncology approach: These variants are associated with con- stitutive pathway activation and are well-established drivers of tumourigenesis.  Targeted therapies should be evaluated based on these molecular findings. Specifically, pharma- ceutical treatment is also recommended to correct hormone imbalances that may be caused by these mutations; However, the clinician's advice takes precedence. Addi- tionally, PI3K inhibitors could be explored in clinical trials for the PIK3CA-mutated context. Further germline testing is not indicated at this time, as all three mutations are consistent with somatic oncogenic events. Multidisciplinary tumour board review is advised to inte grate molecular findings into the patient's treatment plan: Further genetic testing may be required and completed at a physician's discretion: Methodology Genomic DNA was extracted and analyzed using a custom-designed targeted sequenc- ing panel encompassing all coding exons and at least 20 base pairs of flanking intronic regions for the specified genes.  Target enrichment waS performed using hybrid capture technology (Twist Bioscience)  followed by paired-endsequencing on the Illumina NextSeq platform. Sequencing reads were aligned to the GRCh37 /hg19 human genome reference using BWA-MEM, and variant calling was performed using GATK (Broad Institute): Annota- tion and interpretation of variants were conducted using VarSeq (Golden Helix) , incorpo- rating population frequency databases, in silico prediction tools, and ClinVar Exon-level copy number variations were evaluated using CNVkit and confirmed by MLPA (MRC Hol-\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 2\n\nOCH\nMRN:\nDate Collected: 2021-08-17\nNote this is @ draft dataset\nland) when applicable. Regions with known pseudogeneinterference, such as PMS2 , were validated with long-range PCR and Sanger sequencing: The average read depth across all targeted regions exceeded 30Ox , with a minimum depth threshold of 5Ox. The analytical sensitivity for single nucleotide variants and small indels is >o9%, and for exon-level CNVs, >95%, Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, according to ACMGIAMP guidelines (PMID: 25741868). Limitations This test was developed and validated by a certified clinical laboratory: Limitations include reduced sensitivity in regions with pseudogenes (e.g.= PMS2 , CHEK2) , and inability to de tect certain structural variants (e.g. MSH2 inversion) , deep intronic changes, or low-level mosaicism, PMS2 exons 11-15 are not assessed due to pseudogene interference. Variant interpretation reflects current scientific knowledge and may evolve over time.\nOntario Cancer Hospital\nNote that this is @ draft dataset\nPage 3\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2021-08-17\",\n  \"date_received\": \"2021-08-18\",\n  \"date_verified\": \"2021-08-20\",\n  \"report_type\": \"\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"\",\n  \"testing_laboratory\": \"\",\n  \"sequencing_scope\": \"\",\n  \"tested_genes\": {\n    \"SDHA\": {\n      \"gene_symbol\": \"SDHA\",\n      \"refseq_mrna\": \"\"\n    },\n    \"PLCG2\": {\n      \"gene_symbol\": \"PLCG2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CDKN2C\": {\n      \"gene_symbol\": \"CDKN2C\",\n      \"refseq_mrna\": \"\"\n    },\n    \"IDH2\": {\n      \"gene_symbol\": \"IDH2\",\n      \"refseq_mrna\": \"\"\n    },\n    \"AFF1\": {\n      \"gene_symbol\": \"AFF1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"MYH1\": {\n      \"gene_symbol\": \"MYH1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"BCOR\": {\n      \"gene_symbol\": \"BCOR\",\n      \"refseq_mrna\": \"\"\n    },\n    \"OR4A16\": {\n      \"gene_symbol\": \"OR4A16\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LIFR\": {\n      \"gene_symbol\": \"LIFR\",\n      \"refseq_mrna\": \"\"\n    },\n    \"SMAD4\": {\n      \"gene_symbol\": \"SMAD4\",\n      \"refseq_mrna\": \"\"\n    },\n    \"AURKB\": {\n      \"gene_symbol\": \"AURKB\",\n      \"refseq_mrna\": \"\"\n    },\n    \"CDK8\": {\n      \"gene_symbol\": \"CDK8\",\n      \"refseq_mrna\": \"\"\n    },\n    \"POTEF\": {\n      \"gene_symbol\": \"POTEF\",\n      \"refseq_mrna\": \"\"\n    },\n    \"EWSR1\": {\n      \"gene_symbol\": \"EWSR1\",\n      \"refseq_mrna\": \"\"\n    },\n    \"LRIG3\": {\n      \"gene_symbol\": \"LRIG3\",\n      \"refseq_mrna\": \"\"\n    },\n    \"DEK\": {\n      \"gene_symbol\": \"DEK\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KDM4C\": {\n      \"gene_symbol\": \"KDM4C\",\n      \"refseq_mrna\": \"\"\n    },\n    \"KLK2\": {\n      \"gene_symbol\": \"KLK2\",\n      \"refseq_mrna\": \"\"\n    }\n  },\n  \"num_tested_genes\": \"18\",\n  \"sample_type\": \"ctDNA\",\n  \"analysis_type\": \"Karyotyping\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"SDHA\",\n      \"variant_id\": \"VCV001370768\",\n      \"chromosome\": \"chr5\",\n      \"hgvsg\": \"\",\n      \"hgvsc\": \"c.1294G>T\",\n      \"hgvsp\": \"p.Val432Leu\",\n      \"transcript_id\": \"NM_004168.4\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"\",\n      \"mafan\": \"\",\n      \"mafaf\": \"\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"\"\n}\n\nEND\n\n"}
{"prompt": "123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor Sequencing and Diagnostics\ninfo@och,on.ca fax: 416-456-7890 phone: 437-416-6470\nDraft PATHOLOGY LABORATORY RESULTS Patient Info: Patient Information: Name: Physician Name: DOB: Health Card: Sex: MRN #; Clinic: Women's College Hospi- tal (Toronto)\nProcedure Date 2021-08-17\nAccession Date 2021-08- 18\nReport Date 2021-08-20\nReport Details\nGenome Reference NCBI Build 36.1 Sequencing Range Whole transcriptome sequencing (WTS) , Karyotyping\nReferral Reason Clinical\nAnalysis Location Kingston Health Sciences Centre (Kingston) Table of findings: Gene Information Interpretation SDHA C.12946>1 p.Val432Leu heterozy- Likely pathogenic gous\nSummary: One Iikely pathogenic variant detected. The details regarding the specific mutations are included below:\nMRN:\nDate: 2021-08-17\nPage 1\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 Variant Interpretation: The interpretation of these variants is as follows: One likely pathogenic variant was detected in the sample.\nVariant 1 of 1\nGene SDHA\nVariant C.1294G>T\nAmino\nZygosity heterozygous\np.Val432Leu\nLikely pathogenic\nThe 9.219596G>T variant occurs in chromosome chr5 within the SDHA gene, andit causes ,1294G>Tchange at position 432 in exon causing the mutation p.Val432Leu This mutation has been identified in 31 families It has a population frequency of 4.72e-04 (286 alleles in 605686 total alleles tested), indicating it is a relatively common variant in the general population: It causes an amino acid substitution, which replaces valine with leucine ClinVar and other genomic databases report the SDHA c.1294G>T variant as clinically relevant based on aggregated evidence. This variant is classified as likely pathogenic. It is believed to negatively impact protein function and may play a role in disease development in affected indi- viduals, The affected nucleotide lies within a region that is highly conserved across ver- tebrate species, which suggests functional importance and evolutionary con- straint, This variant is implicated in oncogenesis and other disease processes according to ClinVar records (VCV accession: VCVO01370768). Supporting studies and case reports can be found in the scientific literature. Rel- evant PubMedreferences include: 357109863, 166369937,671690943, 134282722\nMRN:\nDate: 2021-08-17\nPage 2\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Division of Tumor info@och,on.ca Sequencing and fax: 416-456-7890 Diagnostics phone: 437-416-6470 In accordance with existing evidence, this variantis therefore classified as a likely pathogenic variant; Test Details:\nGenes Analyzed and mRNA sequence (NM_): SDHA and NM_004168,4, PLCG2 and NM_002661.5. CDKNZC and NM_078626.3. IDH2 and NM_002168.4, AFF] and NM_O01166693.3, MYHI and NM_ 005963.4, BCORand NM_O01123385.2, ORAA16and NM_O01005274.1. LIFR and NM_O01127671.2. SMADAand NM_005359.6. AURKB and NM_004217.4, CDK8 and NM_001260.3, POTEF and NM_001099771,2, EWSR] and NM_005243.4. LRIG3 and NM_153377.5. DEK and NM_003472.4. KDMAC and NM_015061.6. KLK2 and NM_005551.5. 18 total genes tested:\nRecommendations A precision oncology approach is advised. These mutations are known onco- genic drivers, linked to constitutive pathway activation. Targeted therapies, including hormone-correcting agents, may be considered, guided by clinical judgment, PI3K inhibitors could be explored in trials for PIK3CA-mutated cases; Germline testing is not indicated, as all mutations are consistent with somatic events, A multidisciplinary tumour board review is recommended to integrate findings into care. Additional testing may be pursued at the physician's discre- tion; Methodology ctDNA waS sequenced with Whole transcriptome sequencing (WTS) and was analyzed using Karyotyping covering all coding exons and adjacent intronic re- gions. Target enrichment was performed with hybrid capture (Twist Bioscience) , followed by Illumina NextSeq sequencing: Reads were aligned to GRCh37 US - ing BWA-MEM; and variants called with GATK, Annotation was performed in VarSeq using population databases, predictive algorithms, and ClinVar: CNVs were assessed with CNVkit and confirmed by MLPA when applicable. Regions with pseudogene interference , such as PMS2 , were validated using long-range PCR and Sanger sequencing; Mean read depth exceeded 30Ox, with a mini- mum threshold of 5Ox. Analytical sensitivity is >o9% for SNVs/indels and >95% for exon-level CNVs. Only variants classified as pathogenic, likely pathogenic, or variants of uncertain significance (VUS) are reported, per ACMGIAMP guide- lines (PMID: 25741868). Limitations This test waS developed and validated in a certified clinical laboratory: Limi- tations include reduced sensitivity in pseudogene regions (e.g., PMS2 , CHEK2) , and inability to detect certain structuralvariants (e.g., MSH2 inversions) , deep in- tronic changes, or low-level mosaicism; PMS2 exons 11-15 are not analyzed. In-\nMRN:\nDate: 2021-08-17\nPage 3\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: info@och,on.ca Diagnostics phone: 437-416-6470 416-456-7890 terpretations reflect current knowledge and may be updated as new evidence emerges; 1 Mock\nMRN:\nDate: 2021-08-17\nPage 4\n\n123 Main St, West , Toronto, ON, A4B5G9\nToronto Cancer Hospital Sequencing and Division of Tumor fax: 416-456-7890 info@och,on.ca Report Electronically Verified and Signed Diagnostics phone: 437-416-6470 by: 1 Mock\nMRN:\nDate: 2021-08-17\nPage 5\n\n###\n\n", "completion": " {\n  \"date_collected\": \"2021-08-17\",\n  \"date_received\": \"2021-08-18\",\n  \"date_verified\": \"2021-08-20\",\n  \"report_type\": \"Pathology\",\n  \"testing_context\": \"Clinical\",\n  \"ordering_clinic\": \"Women's College Hospital (Toronto)\",\n  \"testing_laboratory\": \"Kingston Health Sciences Centre (Kingston)\",\n  \"sequencing_scope\": \"Whole transcriptome sequencing (WTS)\",\n  \"tested_genes\": {\n    \"SDHA\": {\n      \"gene_symbol\": \"SDHA\",\n      \"refseq_mrna\": \"NM_004168.4\"\n    },\n    \"PLCG2\": {\n      \"gene_symbol\": \"PLCG2\",\n      \"refseq_mrna\": \"NM_002661.5\"\n    },\n    \"CDKN2C\": {\n      \"gene_symbol\": \"CDKN2C\",\n      \"refseq_mrna\": \"NM_078626.3\"\n    },\n    \"IDH2\": {\n      \"gene_symbol\": \"IDH2\",\n      \"refseq_mrna\": \"NM_002168.4\"\n    },\n    \"AFF1\": {\n      \"gene_symbol\": \"AFF1\",\n      \"refseq_mrna\": \"NM_001166693.3\"\n    },\n    \"MYH1\": {\n      \"gene_symbol\": \"MYH1\",\n      \"refseq_mrna\": \"NM_005963.4\"\n    },\n    \"BCOR\": {\n      \"gene_symbol\": \"BCOR\",\n      \"refseq_mrna\": \"NM_001123385.2\"\n    },\n    \"OR4A16\": {\n      \"gene_symbol\": \"OR4A16\",\n      \"refseq_mrna\": \"NM_001005274.1\"\n    },\n    \"LIFR\": {\n      \"gene_symbol\": \"LIFR\",\n      \"refseq_mrna\": \"NM_001127671.2\"\n    },\n    \"SMAD4\": {\n      \"gene_symbol\": \"SMAD4\",\n      \"refseq_mrna\": \"NM_005359.6\"\n    },\n    \"AURKB\": {\n      \"gene_symbol\": \"AURKB\",\n      \"refseq_mrna\": \"NM_004217.4\"\n    },\n    \"CDK8\": {\n      \"gene_symbol\": \"CDK8\",\n      \"refseq_mrna\": \"NM_001260.3\"\n    },\n    \"POTEF\": {\n      \"gene_symbol\": \"POTEF\",\n      \"refseq_mrna\": \"NM_001099771.2\"\n    },\n    \"EWSR1\": {\n      \"gene_symbol\": \"EWSR1\",\n      \"refseq_mrna\": \"NM_005243.4\"\n    },\n    \"LRIG3\": {\n      \"gene_symbol\": \"LRIG3\",\n      \"refseq_mrna\": \"NM_153377.5\"\n    },\n    \"DEK\": {\n      \"gene_symbol\": \"DEK\",\n      \"refseq_mrna\": \"NM_003472.4\"\n    },\n    \"KDM4C\": {\n      \"gene_symbol\": \"KDM4C\",\n      \"refseq_mrna\": \"NM_015061.6\"\n    },\n    \"KLK2\": {\n      \"gene_symbol\": \"KLK2\",\n      \"refseq_mrna\": \"NM_005551.5\"\n    }\n  },\n  \"num_tested_genes\": \"18\",\n  \"sample_type\": \"ctDNA\",\n  \"analysis_type\": \"Karyotyping\",\n  \"variants\": [\n    {\n      \"gene_symbol\": \"SDHA\",\n      \"variant_id\": \"VCV001370768\",\n      \"chromosome\": \"chr5\",\n      \"hgvsg\": \"g.219596G>T\",\n      \"hgvsc\": \"c.1294G>T\",\n      \"hgvsp\": \"p.Val432Leu\",\n      \"transcript_id\": \"NM_004168.4\",\n      \"exon\": \"1\",\n      \"zygosity\": \"heterozygous\",\n      \"interpretation\": \"Likely pathogenic\",\n      \"mafac\": \"286\",\n      \"mafan\": \"605686\",\n      \"mafaf\": \"4.72e-04\"\n    }\n  ],\n  \"num_variants\": \"1\",\n  \"reference_genome\": \"NCBI Build 36.1\"\n}\n\nEND\n\n"}
